WO2023007181A1 - Phenothiazine antipsychotics for use in the treatment of glioblastoma - Google Patents
Phenothiazine antipsychotics for use in the treatment of glioblastoma Download PDFInfo
- Publication number
- WO2023007181A1 WO2023007181A1 PCT/GB2022/052006 GB2022052006W WO2023007181A1 WO 2023007181 A1 WO2023007181 A1 WO 2023007181A1 GB 2022052006 W GB2022052006 W GB 2022052006W WO 2023007181 A1 WO2023007181 A1 WO 2023007181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- optionally substituted
- group
- mmol
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 67
- 208000005017 glioblastoma Diseases 0.000 title claims abstract description 26
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 title description 8
- 229950000688 phenothiazine Drugs 0.000 title description 3
- 239000000164 antipsychotic agent Substances 0.000 title description 2
- 229940005529 antipsychotics Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 218
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 64
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 58
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 26
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims abstract description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 20
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 20
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract description 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 15
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 13
- 150000002367 halogens Chemical class 0.000 claims abstract description 13
- 125000005647 linker group Chemical group 0.000 claims abstract description 13
- 150000001412 amines Chemical class 0.000 claims abstract description 12
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 43
- 229910052794 bromium Inorganic materials 0.000 claims description 30
- 229910052801 chlorine Inorganic materials 0.000 claims description 30
- 229910052731 fluorine Inorganic materials 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 19
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 13
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 13
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 9
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 8
- 206010003571 Astrocytoma Diseases 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000003725 azepanyl group Chemical group 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 53
- 201000011510 cancer Diseases 0.000 abstract description 27
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 24
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 23
- 229910052799 carbon Inorganic materials 0.000 abstract description 15
- 229910052717 sulfur Inorganic materials 0.000 abstract description 6
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 168
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 120
- 239000000203 mixture Substances 0.000 description 88
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 72
- -1 methyl diazonium ions Chemical class 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 53
- 230000015572 biosynthetic process Effects 0.000 description 45
- 238000003786 synthesis reaction Methods 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- 239000002904 solvent Substances 0.000 description 32
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 30
- 239000000284 extract Substances 0.000 description 30
- 125000001424 substituent group Chemical group 0.000 description 26
- 238000003756 stirring Methods 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 21
- 239000012267 brine Substances 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 239000007832 Na2SO4 Substances 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 229910052938 sodium sulfate Inorganic materials 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 238000003760 magnetic stirring Methods 0.000 description 17
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000005457 ice water Substances 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 229960002784 thioridazine Drugs 0.000 description 9
- QAILPAXNHSERDB-UHFFFAOYSA-N 10-(2-chloroethyl)phenothiazine Chemical class C1=CC=C2N(CCCl)C3=CC=CC=C3SC2=C1 QAILPAXNHSERDB-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 8
- 229960003805 amantadine Drugs 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 239000012279 sodium borohydride Substances 0.000 description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 229960004964 temozolomide Drugs 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 231100000111 LD50 Toxicity 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NVRFGQJNKQLUPU-UHFFFAOYSA-N 2-chloro-1-phenothiazin-10-ylethanone Chemical class C1=CC=C2N(C(=O)CCl)C3=CC=CC=C3SC2=C1 NVRFGQJNKQLUPU-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 150000002990 phenothiazines Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000000979 retarding effect Effects 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FATXGYLVHUWCIR-UHFFFAOYSA-N 10-(2-piperidin-1-ylethyl)phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CCN1CCCCC1 FATXGYLVHUWCIR-UHFFFAOYSA-N 0.000 description 3
- FGMRHGUEOYXVMX-UHFFFAOYSA-N 2-(chloromethyl)-1-methylpiperidine Chemical compound CN1CCCCC1CCl FGMRHGUEOYXVMX-UHFFFAOYSA-N 0.000 description 3
- NAQGVVKCOQMRPX-UHFFFAOYSA-N 2-chloro-1-[2-(trifluoromethyl)phenothiazin-10-yl]ethanone Chemical compound C1=CC=C2N(C(=O)CCl)C3=CC(C(F)(F)F)=CC=C3SC2=C1 NAQGVVKCOQMRPX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000004900 autophagic degradation Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- JGIPVPVKVQLMAA-UHFFFAOYSA-N 10-(2-chloroethyl)-2-(trifluoromethyl)phenothiazine Chemical compound C1=CC=C2N(CCCl)C3=CC(C(F)(F)F)=CC=C3SC2=C1 JGIPVPVKVQLMAA-UHFFFAOYSA-N 0.000 description 2
- DLCIJMPSJTVVHJ-UHFFFAOYSA-N 10-(3-chloropropyl)phenothiazine Chemical compound C1=CC=C2N(CCCCl)C3=CC=CC=C3SC2=C1 DLCIJMPSJTVVHJ-UHFFFAOYSA-N 0.000 description 2
- KPHGVVFQTSDDTR-UHFFFAOYSA-N 10-(4-chlorobutyl)phenothiazine Chemical compound C1=CC=C2N(CCCCCl)C3=CC=CC=C3SC2=C1 KPHGVVFQTSDDTR-UHFFFAOYSA-N 0.000 description 2
- RKGYJVASTMCSHZ-UHFFFAOYSA-N 2-(trifluoromethyl)-10H-phenothiazine Chemical compound C1=CC=C2NC3=CC(C(F)(F)F)=CC=C3SC2=C1 RKGYJVASTMCSHZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FXCKKLUGQMWBDD-UHFFFAOYSA-N 2-chloro-1-(2-chlorophenothiazin-10-yl)ethanone Chemical compound C1=C(Cl)C=C2N(C(=O)CCl)C3=CC=CC=C3SC2=C1 FXCKKLUGQMWBDD-UHFFFAOYSA-N 0.000 description 2
- QYHBPNALQOOVBU-UHFFFAOYSA-N 2-chloro-1-(2-methylsulfanylphenothiazin-10-yl)ethanone Chemical compound C1=CC=C2N(C(=O)CCl)C3=CC(SC)=CC=C3SC2=C1 QYHBPNALQOOVBU-UHFFFAOYSA-N 0.000 description 2
- VFBSMNVLCNLCSB-UHFFFAOYSA-N 2-chloro-10-(2-chloroethyl)phenothiazine Chemical compound C1=C(Cl)C=C2N(CCCl)C3=CC=CC=C3SC2=C1 VFBSMNVLCNLCSB-UHFFFAOYSA-N 0.000 description 2
- KFZGLJSYQXZIGP-UHFFFAOYSA-N 2-chloro-10h-phenothiazine Chemical compound C1=CC=C2NC3=CC(Cl)=CC=C3SC2=C1 KFZGLJSYQXZIGP-UHFFFAOYSA-N 0.000 description 2
- OBVKBOLDEFIQDP-UHFFFAOYSA-N 2-methylsulfanyl-10h-phenothiazine Chemical compound C1=CC=C2NC3=CC(SC)=CC=C3SC2=C1 OBVKBOLDEFIQDP-UHFFFAOYSA-N 0.000 description 2
- QDMBCNDXWXEIAF-UHFFFAOYSA-N 3-chloro-1-phenothiazin-10-ylpropan-1-one Chemical compound C1=CC=C2N(C(=O)CCCl)C3=CC=CC=C3SC2=C1 QDMBCNDXWXEIAF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- WLYBVXQXBUACDF-UHFFFAOYSA-N ClCC(=O)N1C2=CC=CC=C2SC=2C=CC(=CC1=2)OC Chemical compound ClCC(=O)N1C2=CC=CC=C2SC=2C=CC(=CC1=2)OC WLYBVXQXBUACDF-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000003373 basosquamous carcinoma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000000339 bright-field microscopy Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000002220 organoid Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102200082402 rs751610198 Human genes 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- HXXJMMLIEYAFOZ-UHFFFAOYSA-N (1-methylpiperidin-2-yl)methanol Chemical compound CN1CCCCC1CO HXXJMMLIEYAFOZ-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XSOHXMFFSKTSIT-UHFFFAOYSA-N 1-adamantylmethanamine Chemical compound C1C(C2)CC3CC2CC1(CN)C3 XSOHXMFFSKTSIT-UHFFFAOYSA-N 0.000 description 1
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- DMHPUUIDINBWBN-UHFFFAOYSA-N 2-ethylsulfanyl-10h-phenothiazine Chemical compound C1=CC=C2NC3=CC(SCC)=CC=C3SC2=C1 DMHPUUIDINBWBN-UHFFFAOYSA-N 0.000 description 1
- DLYKFPHPBCTAKD-UHFFFAOYSA-N 2-methoxy-10H-phenothiazine Chemical compound C1=CC=C2NC3=CC(OC)=CC=C3SC2=C1 DLYKFPHPBCTAKD-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 241000238633 Odonata Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000009198 gamma knife radiosurgery Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 125000001905 inorganic group Chemical group 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000022080 low-grade astrocytoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000003986 lysosome degradation Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002872 norbornadienyl group Chemical group C12=C(C=C(CC1)C2)* 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000012451 post-reaction mixture Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to compounds for use in the treatment of cancer, in particular for use in the treatment of glioblastoma. It further relates to certain novel compounds, to pharmaceutical compositions containing them, and to their use in such treatment. Background to the invention
- Glioblastoma also known as glioblastoma multiforme or “GBM” is an incurable form of brain cancer. It is particularly difficult to treat due to its location and highly aggressive characteristics, however it can be treated for reiief and prolongation of life.
- Conventional treatment involves highly invasive (open brain) surgery, followed by radiation treatment and chemotherapy. Treatment may also involve Gamma Knife radiosurgery in which beams of radiation are highly focused on the tumour thereby minimising radiation damage to surrounding healthy tissues. Surgery is performed to remove as much of the tumour as possible, in high-risk areas of the brain, however, it may not be possible to remove all of the tumour by surgery alone.
- Radiotherapy is used to kill remaining tumour ceils after surgery and can also reduce tumour size, as well as the rate of tumour growth.
- radiotherapy does not have a major effect on tumours such as GBM due to its tendency to spread and the radio-resistance of the cancer cells.
- radiotherapy is not specific in destroying cancerous cells versus normal tissues.
- chemotherapy may also be used although there are relatively few chemotherapeutics in clinical use for the treatment of GBM.
- Temozolomide and the nitrogen mustard ⁇ -chloro-nitrosourea carmustine which are both alkylating agents, can be used as a first line treatment but these are mainly cytostatic as the cancer cells eventually develop resistance and render the treatment no longer effective.
- Temozolomide is a prodrug which is activated by a first pass metabolic decomposition process in the liver that produces methyl diazonium ions which can penetrate the blood-brain barrier. Its mechanism of action involves alkylation of the guanine groups of DNA by the methyl diazonium ions.
- GBM is usually accompanied by recurrence with re- growth of tumours which requires repeated treatment.
- the poor prognosis of GBM is mainly due to the tumour’s high degree of invasiveness and the development of chemotherapy resistance. Tumours such as GBM thus remain particularly difficult to treat and existing therapies only offer a minimal increase in survival rates.
- Thioridazine (Mellaril) is a known antipsychotic drug belonging to the phenothiazine group of drugs. It has the following structure: Thioridazine 10-[2-[(RS)-1-methylpiperidin-2-yl]ethyl]-2-methylsulfanyl-phenothiazine Thioridazine has primarily been used in the treatment of schizophrenia, but also for various psychiatric indications in patients with dementia. However, severe side- effects such as cardiac arrhythmias have been observed leading to its discontinued use. Its serious side-effects suggest that the agent possesses poor selectivity towards its drug target.
- the invention relates to a compound of formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer: (I) wherein: X is CH, S, N or NH; Z is C or N; A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C 1-6 alkylene group in which one or more -CH 2 - groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g.
- each R 1 is independently selected from: C 1-6 alkyl (preferably C 1-3 alkyl, e.g. -CH 3 ), C 2-6 alkenyl (preferably C 2-4 alkenyl), C 2-6 alkynyl (preferably C 2-4 alkynyl), C 1-6 haloalkyl (e.g. -CF 3 ), -O-C 1-6 alkyl (preferably -O-C 1-3 alkyl, e.g. -OCH 3 ), -S-C 1-6 alkyl (preferably -S-C 1-3 alkyl, e.g. -SCH 3 ), -OH, -SH, halogen (e.g.
- n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; R 3 and R 4 are each independently selected from: hydrogen, C 2-6 alkenyl (preferably C 2-4 alkenyl), and C 2-6 alkynyl (preferably C 2-4 alkynyl), or R 3 and R 4 , together with the intervening ring carbon atoms, form an optionally substituted aryl ring (e.g. an optionally substituted phenyl ring); and represents an optional bond between two adjacent carbon atoms in the ring.
- aryl group e.g. optionally substituted phenyl
- n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2
- R 3 and R 4 are each independently selected from: hydrogen, C 2-6 alkenyl (preferably C 2-4 alkenyl), and C 2-6 alkynyl (preferably C 2-4 alkynyl), or R 3 and R 4 , together with the intervening
- the invention relates to a compound of formula (Ia), (Ib) or (Ic) as herein described, a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
- the invention relates to the use of a compound of formula (I), (Ia), (Ib) or (Ic), a stereoisomer, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer.
- the invention relates to a method of treatment of cancer, said method comprising the step of administering to a subject in need thereof (e.g.
- the invention relates to novel compounds of formula (II), their stereoisomers and their pharmaceutically acceptable salts: (II) wherein: A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system, preferably an optionally substituted carbocyclic ring system; L is a linking group which is an optionally substituted C 1-6 alkylene group in which one or more -CH 2 - groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g.
- each R 1 and R 2 is independently selected from: C 1-6 alkyl (preferably C 1-3 alkyl, e.g. -CH 3 ), C 2-6 alkenyl (preferably C 2-4 alkenyl), C 2-6 alkynyl (preferably C 2-4 alkynyl), C 1-6 haloalkyl (e.g. -CF 3 ), -O-C 1-6 alkyl (preferably -O-C 1-3 alkyl, e.g. -OCH 3 ), -S-C 1-6 alkyl (preferably -S-C 1-3 alkyl, e.g. -SCH 3 ), -OH, -SH, halogen (e.g.
- n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; with the proviso that the compound is other than thioridazine.
- the invention relates to a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in therapy or for use as a medicament.
- the invention in another aspect, relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers, excipients or diluents.
- alkyl refers to a saturated hydrocarbon group and is intended to cover both straight-chained and branched alkyl groups.
- Examples of such groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, sec-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-methylbutyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl.
- An alkyl group preferably contains from 1-6 carbon atoms, more preferably 1-4 carbon atoms, e.g.1-3 carbon atoms. Unless otherwise specified, any alkyl group may be substituted in one or more positions with a suitable substituent.
- substituents include -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- alkenyl refers to an alkyl group having one or more carbon-carbon double bonds and includes both straight-chained and branched alkenyl groups.
- C 2-6 alkenyl refers to an alkenyl group having from 2 to 6 carbon atoms and one or more (e.g. one or two) double bonds.
- any alkenyl group mentioned herein may optionally be substituted by one or more groups, which may be identical or different.
- Suitable substituents include -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- alkynyl refers to an alkyl group having one or more carbon-carbon triple bonds and includes both straight-chained and branched alkynyl groups. Unless otherwise stated, any alkynyl group mentioned herein may optionally be substituted by one or more groups, which may be identical or different. Suitable substituents include -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- the term “carbocyclic ring system” as used herein refers to a monovalent, saturated or unsaturated cyclic carbon system. Such systems may include one or more carbon-containing rings.
- any carbocyclic ring system may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different. Suitable substituents include -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- the term “heterocyclic ring system” as used herein refers to a monovalent, saturated or unsaturated cyclic carbon system in which one or more carbon atoms are replaced by a heteroatom selected from oxygen, nitrogen or sulfur, preferably nitrogen.
- Such systems may include one or more rings in which at least one ring contains at least one heteroatom. Where more than one ring is present the rings may be linked by a bond or they may be fused. Unless otherwise specified, any heterocyclic ring system may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different. Suitable substituents include -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- cycloalkyl refers to a monovalent, saturated cyclic carbon system. It includes monocyclic, bicyclic and polycyclic (e.g.
- Monocyclic rings may contain from 3 to 8 carbon atoms, bicyclic rings may contain from 7 to 14 carbon atoms, and tricyclic rings may contain from 10 to 14 carbon atoms. Where these contain more than one ring, the rings may be fused or bridged. In fused compounds, two rings share two adjacent atoms. In bridged compounds, two rings share three or more atoms thereby forming a bridge which contains at least one atom.
- monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.
- bicyclic cycloalkyl groups include, but are not limited to, norbornyl.
- tricyclic cycloalkyl groups include, but are not limited to, adamantyl.
- any cycloalkyl group may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different.
- Suitable substituents include -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- cycloalkenyl refers to a monovalent, partially unsaturated cyclic carbon system.
- any cycloalkenyl group may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different. Suitable substituents include -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- alkylene refers to a linking alkyl group and is intended to cover any straight-chained or branched alkylene group.
- Such groups include methylene, ethylene, ethane-1,1-diyl, propylene, propane-2,2-diyl, 1- methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2- dimethylethylene, etc.
- Such groups may optionally be substituted by one or more groups selected from -O-C 1-3 alkyl and halogen atoms (e.g. F, Cl or Br).
- halogen or “halogen atom” as used herein refers to -F, -Cl, -Br or -I.
- haloalkyl refers to an alkyl group as defined herein in which at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably F, Cl or Br. Examples of such groups include -CH 2 F, -CHF 2 , -CF 3 , -CCl 3 , -CHCl 2 , -CH 2 CF 3 , etc.
- aryl refers to aromatic ring systems. Such ring systems may be monocyclic or bicyclic and contain at least one unsaturated aromatic ring. Where these contain bicyclic rings, these may be fused. Preferably such systems contain from 6-20 carbon atoms, e.g. either 6 or 10 carbon atoms.
- heterocyclic ring refers to a saturated or partially unsaturated, 4- to 6-membered (preferably 5- or 6-membered) carbocyclic system in which at least one ring atom is a heteroatom selected from nitrogen, oxygen and sulfur, the remaining ring atoms being carbon.
- the heterocyclic ring structure may be linked to the remainder of the molecule through a carbon atom or through a nitrogen atom.
- heterocyclic rings include, but are not limited to, tetrahydrofuran, piperidine, pyrrolidine, dioxane, morpholine, etc.
- any heterocyclic ring mentioned herein may optionally be substituted by one or more groups, which may be identical or different, for example hydroxy, C 1-6 alkyl, C 1-6 alkoxy, amino, cyano, or nitro groups, or halogen atoms (e.g. F, Cl or Br).
- halogen atoms e.g. F, Cl or Br.
- all substituents are independent of one another. In the case where a subscript is the integer 0 (i.e. zero), it is intended that the group to which the subscript refers is absent.
- stereoisomer refers to compounds which have identical chemical constitution but which differ in respect of the spatial arrangement of the atoms or groups. Examples of stereoisomers are enantiomers and diastereomers.
- enantiomers refers to two stereoisomers of a compound which are non-superimposable mirror images of one another.
- diastereoisomers refers to stereoisomers with two or more stereocenters which are not mirror images of one another.
- the invention is considered to extend to diastereomers and enantiomers, as well as racemic mixtures and enantioenriched mixtures in which the ratio of enantiomers is other than 1:1.
- the compounds herein described may be resolved into their enantiomers and/or diastereomers. For example, where these contain only one chiral center, these may be provided in the form of a racemate or racemic mixture (a 50:50 mixture of enantiomers) or may be provided as pure enantiomers, i.e. in the R- or S-form. Any of the compounds which occur as racemates may be separated into their enantiomers by methods known in the art, such as column separation on chiral phases or by recrystallization from an optically active solvent.
- Those compounds with at least two asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallization, and where these compounds are obtained in racemic form, they may subsequently be resolved into their enantiomers.
- pharmaceutically acceptable salt refers to any pharmaceutically acceptable organic or inorganic salt of any of the compounds herein described.
- a pharmaceutically acceptable salt may include one or more additional molecules such as counter-ions.
- the counter-ions may be any organic or inorganic group which stabilises the charge on the parent compound. If the compound is a base, a suitable pharmaceutically acceptable salt may be prepared by reaction of the free base with an organic or inorganic acid.
- a suitable pharmaceutically acceptable salt may be prepared by reaction of the free acid with an organic or inorganic base.
- suitable salts are described herein.
- pharmaceutically acceptable means that the compound or composition is chemically and/or toxicologically compatible with other components of the formulation or with the patient to be treated.
- a pharmaceutical composition is meant a composition in any form suitable to be used for a medical purpose.
- cancer refers to cells undergoing abnormal proliferation. Growth of such cells typically causes the formation of a tumor. Cancerous cells may be benign, pre-malignant or malignant. Such cells may be invasive and/or have the ability to metastasize to other locations in the body.
- cancer includes cancerous growths, tumours, and their metastases.
- tumor refers to an abnormal mass of tissue containing cancerous cells.
- metastasis refers to the spread of malignant tumour cells from one organ or part of the body to another non-adjacent organ or part of the body. Cancer cells may break away from a primary tumour, enter the lymphatic and blood systems and circulate to other parts of the body (e.g. to normal tissues). Here they may settle and grow within the normal tissues. When tumour cells metastasize, the new tumours may be referred to as a “secondary” or metastatic cancer or tumour.
- treatment includes any therapeutic application that can benefit a human or non-human animal (e.g. a non-human mammal). Both human and veterinary treatments are within the scope of the present invention, although primarily the invention is aimed at the treatment of humans. Where not explicitly stated, treatment encompasses prevention.
- a “pharmaceutically effective amount” relates to an amount that will lead to the desired pharmacological and/or therapeutic effect, i.e. an amount of the agent which is effective to achieve its intended purpose. While individual subject (e.g. patient) needs may vary, determination of optimal ranges for effective amounts of the active agent(s) herein described is within the capability of one skilled in the art.
- the dosage regimen for treating a disease, condition or disorder with any of the compounds described herein may be selected by those skilled in the art in accordance with a variety of factors including the nature of the condition and its severity.
- the term “subject” refers to any individual who is the target of the administration or treatment.
- the subject may be, for example, a mammal.
- the subject may be a human or non-human animal.
- the term “patient” refers to a subject under the treatment of a clinician.
- the subject will be a human.
- the invention relates to a compound of formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer:
- X is CH, S, N or NH; Z is C or N; A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C 1-6 alkylene group in which one or more -CH 2 - groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g. methyl); each R 1 is independently selected from: C 1-6 alkyl (preferably C 1-3 alkyl, e.g.
- C 2-6 alkenyl preferably C 2-4 alkenyl
- C 2-6 alkynyl preferably C 2-4 alkynyl
- C 1-6 haloalkyl e.g. -CF 3
- -O-C 1-6 alkyl preferably -O-C 1-3 alkyl, e.g. -OCH 3
- -S-C 1-6 alkyl preferably -S-C 1-3 alkyl, e.g. -SCH 3
- an optionally substituted aryl group e.g.
- n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; R 3 and R 4 are each independently selected from: hydrogen, C 2-6 alkenyl (preferably C 2-4 alkenyl), and C 2-6 alkynyl (preferably C 2-4 alkynyl), or R 3 and R 4 , together with the intervening ring carbon atoms, form an optionally substituted aryl ring (e.g. an optionally substituted phenyl ring); and represents an optional bond between two adjacent carbon atoms in the ring.
- the compounds for use according to the invention are those of formula (I) in which R 3 and R 4 are both hydrogen.
- the compounds for use according to the invention are those of formula (I) in which R 3 and R 4 , together with the intervening ring carbon atoms, form an optionally substituted aryl group.
- the aryl group which is formed can be an optionally substituted phenyl ring.
- the compounds for use according to the invention are those of formula (Ia), their stereoisomers, or pharmaceutically acceptable salts thereof: (Ia) wherein X, Z, A, L, R 1 and n are as herein defined; represents an optional bond between two adjacent carbon atoms in the ring; R 2 is selected from any of the groups defined herein for R 1 ; and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2.
- the compounds for use according to the invention are those of formula (I) or (Ia) in which X is CH or S, preferably S.
- the compounds for use according to the invention are those of formula (I) or (Ia) in which X is S and Z is N.
- the compounds for use according to the invention are based on a phenothiazine scaffold.
- Such compounds are those of formula (Ib), their stereoisomers, or pharmaceutically acceptable salts thereof: (Ib) wherein A, L, R 1 , R 2 , n and m are as herein defined.
- the compounds for use according to the invention are those of formula (I) or (Ia) in which X is CH and Z is C.
- the compounds for use according to the invention are based on an anthracene scaffold.
- Such compounds are those of formula (Ic), their stereoisomers, and pharmaceutically acceptable salts thereof: (Ic) wherein A, L, R 1 , R 2 , n and m are as herein defined.
- group A may be an optionally substituted amine.
- group A may be a group of the formula -NR a R b wherein R a and R b are independently selected from H, optionally substituted C 1-6 alkyl, and optionally substituted aryl.
- group A may be an optionally substituted carbocyclic or heterocyclic ring system.
- Such ring systems may comprise from 3 to 14 ring atoms, preferably from 5 to 12 ring atoms, e.g. from 6 to 14 ring atoms.
- group A is an optionally substituted carbocyclic ring system.
- group A may be an optionally substituted cycloalkyl or cycloalkenyl group.
- Such groups may be mono-, bi- or tricyclic. Where more than one ring is present, these may be bridged or fused.
- A is a cycloalkyl group containing two or three rings which are fused or bridged.
- A is an optionally substituted aryl group. For example, it may be an optionally substituted phenyl ring.
- A is an optionally substituted heterocyclic group.
- Such groups may be mono-, bi- or poly-cyclic. Where more than one ring is present, these may be bridged or fused. Such groups may be saturated or unsaturated.
- Non-limiting examples of group A include adamantyl, phenyl, quinuclidinyl (1- azabicyclo[2.2.2]octanyl), DABCO (1,4-diazabicyclo[2.2.2]octanyl), tropanyl (N- methyl-8-azabicyclo[3.2.1]octanyl), nortropanyl (8-azabicyclo[3.2.1]octanyl), norbornyl, norbornenyl, norbornadienyl, bornyl, pyrrolyl, pyrrolidinyl, piperidinyl, pyridinyl, morpholinyl, azepanyl (azacycloheptanyl), decahydroquinolyl, azonanyl, octahydrocyclopenta[c]pyrrolyl, azecanyl, octahydropyrrolo[3,4-c]pyrrolyl
- group A is selected from substituted or unsubstituted adamantyl, phenyl, quinuclidinyl, piperidinyl and azepanyl. In another embodiment, group A is substituted or unsubstituted adamantyl or piperidinyl, preferably substituted or unsubstituted adamantyl. In one embodiment, group A is unsubstituted adamantyl. Group A may be bonded to group L either through a ring carbon or ring nitrogen atom. In one embodiment, group A is bonded to the group L via a ring carbon atom. Group A may be substituted or unsubstituted.
- substituent groups may be present on the ring.
- Each substituent may, independently of one another, be linked either to a ring carbon atom or to a ring nitrogen atom.
- group A is substituted by one or more groups independently selected from -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- Preferred substituents include, but are not limited to, methyl, ethyl, n-propyl and isopropyl groups.
- group A is not substituted at any ring carbon atom.
- group A is not substituted at any point on the ring, i.e. it is unsubstituted.
- the presence of a hydrogen atom on a ring nitrogen atom is not considered to be a “substituent”.
- Preferred examples of group A include the following (where denotes the point of attachment to the rest of the molecule):
- Linking group L serves to link the group A to the remainder of the molecule.
- Group L may be an optionally substituted, straight-chained or branched C 1-6 alkylene group.
- L is an optionally substituted, straight-chained or branched C 1-3 alkylene group.
- linking group L is an unsubstituted, straight-chained C 1-6 alkylene group, preferably an unsubstituted, straight-chained C 1-3 alkylene group, such as methylene or ethylene.
- L may be an optionally substituted C 1-6 alkylene group, preferably C 2-6 alkylene group, in which one or more -CH 2 - groups of the alkylene chain are replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g. methyl).
- L may be an optionally substituted C 2-6 alkylene, C 3-6 alkylene or C 4-6 alkylene group in which one or more -CH 2 - groups of the alkylene chain are replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g. methyl).
- R’ is H or C 1-3 alkyl, e.g. methyl
- the alkylene chain is straight-chained.
- group L may be propylene or butylene in which one or two of the -CH 2 - groups are replaced by a group -NR’-, preferably by a group -NH- or -N(CH 3 )-.
- group L may be pentylene in which one or two of the -CH 2 - groups are replaced by a group -NR’-, preferably by a group -NH- or -N(CH 3 )-.
- one or more -CH 2 - groups of the alkylene chain in group L are replaced by a group -NR’- (where R’ is H or C 1-3 alkyl, e.g. methyl).
- one or two -CH 2 - groups of the alkylene chain are replaced by such a group.
- linking group L include the following (where denotes the point of attachment to the rest of the molecule):
- Other examples of linking group L include the following (where denotes the point of attachment to the rest of the molecule):
- substituent groups R 1 and R 2 may be the same or different.
- each R 1 is independently selected from: C 1-6 alkyl (preferably C 1-3 alkyl, e.g. -CH 3 ), C 1-6 haloalkyl (e.g. -CF 3 ), -O-C 1-6 alkyl (preferably -O-C 1-3 alkyl, e.g.
- each R 1 is independently selected from C 1-3 alkyl (e.g. -CH 3 ), -CF 3 , -O-C 1-3 alkyl (e.g. -OCH 3 or -OCH 2 CH 3 ), -S-C 1-3 alkyl (e.g. -SCH 3 or -SCH 2 CH 3 ), F, Cl, Br and phenyl.
- each R 1 is independently selected from -CH 3 , -CF 3 , -OCH 3 , -SCH 3 , and -SCH 2 CH 3 .
- n is selected from 0, 1 or 2, preferably 0 or 1.
- each R 2 where present, is independently selected from C 1-3 alkyl (e.g. -CH 3 ), -CF 3 , -O-C 1-3 alkyl (e.g. -OCH 3 or -OCH 2 CH 3 ), -S-C 1-3 alkyl (e.g. -SCH 3 or -SCH 2 CH 3 ), F, Cl, Br and phenyl.
- each R 2 is independently selected from -CH 3 , -CF 3 , -OCH 3 , -SCH 3 , and -SCH 2 CH 3 .
- m is selected from 0, 1 or 2, preferably 0 or 1. Examples of compounds for use in accordance with the invention include, but are not limited to, the following, their stereoisomers, and their pharmaceutically acceptable salts:
- the present invention provides compounds of formula (II), their stereoisomers and their pharmaceutically acceptable salts: (II) wherein: A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C 1-6 alkylene group in which one or more -CH 2 - groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g.
- each R 1 and R 2 is independently selected from: C 1-6 alkyl (preferably C 1-3 alkyl, e.g. -CH 3 ), C 2-6 alkenyl (preferably C 2-4 alkenyl), C 2-6 alkynyl (preferably C 2-4 alkynyl), C 1-6 haloalkyl (e.g. -CF 3 ), -O-C 1-6 alkyl (preferably -O-C 1-3 alkyl, e.g. -OCH 3 ), -S-C 1-6 alkyl (preferably -S-C 1-3 alkyl, e.g. -SCH 3 ), -OH, -SH, halogen (e.g.
- n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; with the proviso that the compound is other than thioridazine.
- the compound of formula (II) is other than 10-((1- methylpiperidin-2-yl)methyl)-2-(methylthio)-10H-phenothiazine or 10-(2-(piperidin-1- yl)ethyl)-10H-phenothiazine.
- the invention provides compounds of formula (II), their stereoisomers and their pharmaceutically acceptable salts, in which A is an optionally substituted carbocyclic ring system.
- A is an optionally substituted cycloalkyl group, for example an optionally substituted cycloalkyl group containing two or three rings which are fused or bridged.
- A is substituted or unsubstituted adamantyl, for example unsubstituted adamantyl.
- the invention relates to a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in therapy or for use as a medicament.
- the invention relates to a pharmaceutical composition comprising a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers, excipients or diluents. Any of the compounds herein described may be converted into a salt thereof, particularly into a pharmaceutically acceptable salt thereof with an inorganic or organic acid or base.
- Acids which may be used for this purpose include hydrochloric acid, hydrobromic acid, sulfuric acid, sulfonic acid, methane sulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, maleic acid, acetic acid, trifluoroacetic acid and ascorbic acid.
- Bases which may be suitable for this purpose include alkali and alkaline earth metal hydroxides, e.g. sodium hydroxide, potassium hydroxide or cesium hydroxide, ammonia and organic amines such as diethylamine, triethylamine, ethanolamine, diethanolamine, cyclohexylamine and dicyclohexylamine.
- Procedures for salt formation are conventional in the art.
- the compounds described herein may exist in various stereoisomeric forms, including enantiomers, diastereomers, and mixtures thereof.
- the invention encompasses all optical isomers of the compounds described herein and mixtures of optical isomers. Hence, compounds that exist as diastereomers, racemates and/or enantiomers are within the scope of the invention.
- the compounds for use in the invention are either known in the art, or can be prepared by methods known to those skilled in the art using readily available starting materials. Some of the compounds for use in the invention may be commercially available.
- R 1 , R 2 , A and n are as herein defined, and w is an integer from 0-5.
- R 1 , R 2 , R 3 , R 4 , A, L and n are as herein defined.
- R 1 , R 2 , R 3 , R 4 , A, L and n are as herein defined; and X is a halogen atom.
- Cancers which may be treated in accordance with the invention include, but are not limited to, any of the following: leukemias, lymphomas, colon cancer (e.g. colorectal cancer), breast cancer, glioblastoma, pancreatic cancer, bladder cancer, lung cancer and skin cancer.
- Metastatic disease arising from any of these tumours may also be treated using any of the compounds herein described.
- the invention finds particular use in the treatment of deep lying cancerous lesions that are difficult to access non-invasively.
- Treatment of gliomas forms a preferred aspect of the invention.
- the compounds described herein find use in the treatment of glioblastoma in a subject or patient and, in particular, in the treatment or prevention of astrocytomas, oligodendrogliomas or ependymomas.
- the compounds described herein can be used in the treatment of astrocytomas, such as pliocytic astrocytoma, diffuse or low grade astrocytoma, anaplastic astrocytoma or grade 4 astrocytoma.
- astrocytomas such as pliocytic astrocytoma, diffuse or low grade astrocytoma, anaplastic astrocytoma or grade 4 astrocytoma.
- the compounds described herein also find particular use in the treatment of skin cancers, for example in the treatment of basal cell carcinoma, squamous cell carcinoma, and melanoma.
- a “subject” or “patient” encompasses any animal, preferably a mammal. Examples of mammalian subjects include, without limitation, humans, dogs, cats, rodents (e.g.
- the compounds of the invention are suitable for preventing and/or retarding cancer cell proliferation, differentiation and/or survival, or for preventing and/or retarding metastasis of cancer cells.
- proliferation refers to cells undergoing mitosis.
- retarding proliferation indicates that the compounds inhibit proliferation of a cancer cell.
- "retarding proliferation” indicates that DNA replication is at least 10% less than that observed in untreated cells, more preferably at least 25% less, yet more preferably at least 50% less, e.g.75%, 90% or 95% less than that observed in untreated cancer cells.
- the compounds herein described will typically be formulated as a pharmaceutical formulation together with one or more pharmaceutically acceptable carriers, excipients or diluents. Acceptable carriers, excipients and diluents for therapeutic use are well known in the art and can be selected with regard to the intended route of administration and standard pharmaceutical practice.
- compositions will be adapted for oral or parenteral administration, for example by intradermal, subcutaneous, intraperitoneal, or intravenous injection.
- these may be formulated in conventional oral administration forms, e.g.
- compositions may be prepared using conventional techniques, such as dissolution and/or mixing procedures. Where parenteral administration is employed this may, for example, be by means of intravenous, subcutaneous, intraperitoneal or intramuscular injection. For this purpose, sterile solutions containing the active agent may be employed, such as an oil-in-water emulsion.
- an appropriate buffer system e.g., sodium phosphate, sodium acetate or sodium borate
- an appropriate buffer system e.g., sodium phosphate, sodium acetate or sodium borate
- Compounds having a partition coefficient, Log P, greater than or equal to 3 and less than or equal to 5 are particularly suitable for oral administration due to their ability to cross the blood brain barrier.
- any pharmaceutical formulation may be administered locally (e.g. by injection or topically) at or near the affected site.
- Topical pharmaceutical formulations include gels, creams, ointments, sprays, lotions, salves, sticks, powders, solutions and any of the other conventional pharmaceutical forms in the art.
- Ointments, gels and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Any thickening or gelling agents used should be non-toxic and non-irritant.
- Lotions may be formulated with an aqueous or oily base and will, in general, also contain one or more emulsifying, dispersing, suspending, thickening or colouring agents. Powders may be formed with the aid of any suitable powder base.
- Sprays and solutions may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing, solubilising or suspending agents.
- the formulations herein described may be prepared using conventional techniques, such as dissolution and/or mixing procedures, tableting, etc.
- the dosage required to achieve the desired activity of the compounds herein described will depend on various factors, such as the compound selected, its mode and frequency of administration, whether the treatment is therapeutic or prophylactic, and the nature and severity of the disease or condition, etc.
- a physician will determine the actual dosage which will be most suitable for an individual subject.
- the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon factors such as the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age of the patient, the mode and time of administration, and the severity of the particular condition.
- the compound and/or the pharmaceutical composition may be administered in accordance with a regimen from 1 to 10 times per day, such as once or twice per day.
- the daily dosage level of the agent may be in single or divided doses.
- Suitable daily dosages of the compounds herein described may readily be determined by those skilled in the art, but are expected to be in the range from 0.1 mg to 1 g of the compound; 1 mg to 500 mg of the compound; 1 mg to 300 mg of the compound; 5 mg to 100 mg of the compound, or 10 mg to 50 mg of the compound.
- a “daily dosage” is meant the dosage per 24 hours.
- Embodiments of the invention include, but are not limited to, the following: Embodiment 1: A compound of formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer: (I) wherein: X is CH, S, N or NH; Z is C or N; A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C 1-6 alkylene group in which one or more -CH 2 - groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g.
- each R 1 is independently selected from: C 1-6 alkyl (preferably C 1-3 alkyl, e.g. -CH 3 ), C 2-6 alkenyl (preferably C 2-4 alkenyl), C 2-6 alkynyl (preferably C 2-4 alkynyl), C 1-6 haloalkyl (e.g. -CF 3 ), -O-C 1-6 alkyl (preferably -O-C 1-3 alkyl, e.g. -OCH 3 ), -S-C 1-6 alkyl (preferably -S-C 1-3 alkyl, e.g. -SCH 3 ), -OH, -SH, halogen (e.g.
- n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2;
- R 3 and R 4 are each independently selected from: hydrogen C 2-6 alkenyl (preferably C 2-4 alkenyl), and C 2-6 alkynyl (preferably C 2-4 alkynyl), or R 3 and R 4 , together with the intervening ring carbon atoms, form an optionally substituted aryl ring (e.g. an optionally substituted phenyl ring); and represents an optional bond between two adjacent carbon atoms in the ring.
- Embodiment 2 A compound for use as described in embodiment 1, wherein R 3 and R 4 , together with the intervening ring carbon atoms, form an optionally substituted aryl group.
- Embodiment 3 A compound for use as described in embodiment 1 or embodiment 2 which is a compound of formula (Ia), a stereoisomer, or a pharmaceutically acceptable salt thereof: (Ia) wherein X, Z, A, L, R 1 and n are as defined in embodiment 1; represents an optional bond between two adjacent carbon atoms in the ring; each R 2 is independently selected from: C 1-6 alkyl (preferably C 1-3 alkyl, e.g.
- C 2-6 alkenyl preferably C 2-4 alkenyl
- C 2-6 alkynyl preferably C 2-4 alkynyl
- C 1-6 haloalkyl e.g. -CF 3
- -O-C 1-6 alkyl preferably -O-C 1-3 alkyl, e.g. -OCH 3
- -S-C 1-6 alkyl preferably -S-C 1-3 alkyl, e.g. -SCH 3
- an optionally substituted aryl group e.g.
- Embodiment 4 A compound for use as described in any one of embodiments 1 to 3, wherein X is CH or S, preferably S.
- Embodiment 5 A compound for use as described in embodiment 4 which is a compound of formula (Ib), a stereoisomer, or a pharmaceutically acceptable salt thereof: wherein A, L, R 1 and n are as defined in embodiment 1; and R 2 and m are as defined in embodiment 3.
- Embodiment 6 A compound for use as described in any one of embodiments 1 to 3 which is a compound of formula (Ic), a stereoisomer, or a pharmaceutically acceptable salt thereof: wherein A, L, R 1 and n are as defined in embodiment 1; and R 2 and m are as defined in embodiment 3.
- Embodiment 7 A compound for use as described in any one of embodiments 1 to 6, wherein A is an optionally substituted carbocyclic or heterocyclic ring system.
- Embodiment 8 A compound for use as described in embodiment 7, wherein A is an optionally substituted cycloalkyl or cycloalkenyl group, preferably an optionally substituted cycloalkyl group containing two or three rings which are fused or bridged.
- Embodiment 9 A compound for use as described in embodiment 7, wherein A is an optionally substituted heterocyclic group.
- Embodiment 10 A compound for use as described in embodiment 8 or embodiment 9, wherein A is selected from substituted or unsubstituted adamantyl, phenyl, quinuclidinyl, piperidinyl and azepanyl.
- Embodiment 11 A compound for use as described in any one of embodiments 1 to 10, wherein A is substituted by one or more groups independently selected from -OH, C 1-6 alkyl, -O-C 1-6 alkyl, C 1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
- halogen atoms e.g. F, Cl or Br
- Embodiment 12 A compound for use as described in any one of embodiments 1 to 11, wherein A is selected from the following: .
- Embodiment 13 A compound for use as described in any one of embodiments 1 to 12, wherein L is an optionally substituted, straight-chained or branched C 1-6 alkylene group.
- Embodiment 14 A compound for use as described in any one of embodiments 1 to 12, wherein L is an optionally substituted C 1-6 alkylene group, preferably C 2-6 alkylene group, in which one or more -CH 2 - groups of the alkylene chain are replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g. methyl).
- Embodiment 15 A compound for use as described in any one of embodiments 1 to 14, wherein L is selected from the following:
- Embodiment 16 A compound for use as described in any one of embodiments 1 to 15, wherein each R 1 is independently selected from C 1-3 alkyl (e.g. -CH 3 ), -CF 3 , -O- C 1-3 alkyl (e.g. -OCH 3 or -OCH 2 CH 3 ), -S-C 1-3 alkyl (e.g. -SCH 3 or -SCH 2 CH 3 ), F, Cl, Br and phenyl.
- Embodiment 17 A compound for use as described in any one of embodiments 1 to 16, wherein n is 0, 1 or 2, preferably 0 or 1.
- Embodiment 18 A compound for use as described in any one of embodiments 3 to 17, wherein each R 2 is independently selected from C 1-3 alkyl (e.g. -CH 3 ), -CF 3 , -O- C 1-3 alkyl (e.g. -OCH 3 or -OCH 2 CH 3 ), -S-C 1-3 alkyl (e.g. -SCH 3 or -SCH 2 CH 3 ), F, Cl, Br and phenyl.
- Embodiment 19 A compound for use as described in any one of embodiments 3 to 18, wherein m is 0, 1 or 2, preferably 0 or 1.
- Embodiment 20 A compound for use as described in embodiment 1 which is selected from the following compounds, their stereoisomers, and their pharmaceutically acceptable salts:
- Embodiment 21 A compound for use as described in any one of embodiments 1 to 20, wherein said cancer is selected from the group consisting of: leukemias, lymphomas, colon cancer, breast cancer, glioblastoma, pancreatic cancer, bladder cancer, lung cancer and skin cancer.
- Embodiment 22 A compound for use as described in embodiment 21 in the treatment of glioblastoma, preferably in the treatment of an astrocytoma, oligodendroglioma or ependymoma.
- Embodiment 23 A compound for use as described in embodiment 21 in the treatment of basal cell carcinoma, squamous cell carcinoma, or melanoma.
- Embodiment 24 A compound of formula II, a stereoisomer or a pharmaceutically acceptable salt thereof: (II) wherein: A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C 1-6 alkylene group in which one or more -CH 2 - groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C 1-3 alkyl, e.g. methyl); each R 1 and R 2 is independently selected from: C 1-6 alkyl (preferably C 1-3 alkyl, e.g.
- C 2-6 alkenyl preferably C 2-4 alkenyl
- C 2-6 alkynyl preferably C 2-4 alkynyl
- C 1-6 haloalkyl e.g. -CF 3
- -O-C 1-6 alkyl preferably -O-C 1-3 alkyl, e.g. -OCH 3
- -S-C 1-6 alkyl preferably -S-C 1-3 alkyl, e.g. -SCH 3
- an optionally substituted aryl group e.g.
- Embodiment 25 A pharmaceutical composition comprising a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof as described in embodiment 24, together with one or more pharmaceutically acceptable carriers, excipients or diluents.
- Figure 1 Monitoring cell growth and morphology during treatment with 4 ⁇ M Compound EA01 after treatment for 72 h.
- A Left: Normal Human Astrocytes (NHA) (DMEM alt), right: NHA with 4 ⁇ M Compound EA01.
- B Left: U87-MG Control (DMEM alt), right: U87-MG with 4 ⁇ M Compound EA01.
- C Left: U251 Control (DMEM alt), right: U251 with 4 ⁇ M Compound EA01.
- B 72 h values of change fold confluency.
- Step 1 – method A The 10H-phenothiazine derivative (1 eq.) 1 was treated with chloroacetyl chloride (2.7 eq.) 2 under microwave irradiation. When the microwave reaction was finished, water was added and the mixture was extracted with ethyl acetate, the extracts were combined and washed with brine. The organic layer was dried over Na 2 SO 4 , filtered, and the solvent removed in vacuo. The compound 3 was purified by recrystallization in methanol.
- Step 1 – method B The 10H-phenothiazine derivative (1 eq.) 1 and toluene were added to a round bottle flask equipped with a magnetic stirring bar. The mixture was then placed in an ice-water bath and stirred while chloroacetyl chloride (1.5 eq.) 2 was carefully added by a syringe. The mixture was heated and left stirring. The mixture was then cooled to room temperature and the solvent was removed in vacuo. The compound 3 was then purified by recrystallization in methanol.
- Step 2 The 2-chloro-1-(10H-phenothiazin-10-yl)ethan-1-one derivative (1 eq.) 3 and dry THF were added to a dry round bottle flask equipped with a magnetic stirring bar. The mixture was flushed with nitrogen, put in an ice water bath and BF 3 •Et 2 O (1.5 eq.) carefully added by syringe while stirring. NaBH 4 (1.2 eq.) was added and the mixture was stirred before it was put in an ultrasonic bath. After removing the mixture from the ultrasonic bath, it was quenched with NaHCO 3 and extracted with ethyl acetate.
- Step 3 – method A The 10-(2-chloroethyl)-10H-phenothiazine derivative (1 eq.) 4, KI (1 eq.), amine (5 eq.) and DMF were added to a round bottle flask equipped with a magnetic stirrer. The mixture was heated and left stirring. When the reaction was finished it was cooled to room temperature and an aqueous solution of NH 4 Cl was added, before it was extracted with ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO 4 . The organic extracts were filtered, and the solvent removed in vacuo.
- the compound 5 was purified using flash column chromatography.
- Step 3 – method B The 10-(2-chloroethyl)-10H-phenothiazine derivative (1 eq.) 4, amine (5 eq.), K 2 CO 3 (5.5 eq.), KI (1 eq.) and THF were added to a round bottle flask equipped with a condenser and a magnetic stirrer. The mixture was heated to reflux and stirred. When the reaction was finished it was cooled to room temperature and water added before it was extracted with ethyl acetate. The organic extracts were dried over Na 2 SO 4 , filtered and the solvent was removed in vacuo. The compound 5 was purified using flash column chromatography.
- Example 1 Synthesis of N-(2-(10H-Phenothiazin-10-yl)ethyl)adamantan-1-amine (Compound EA01) Synthesis of 2-chloro-1-(10H-phenothiazin-10-yl)ethan-1-one: 10H-phenothiazine (0.373 g, 1.87 mmol) and 5 mL of chlorobenzene were added to a microwave vial (20 mL) together with a magnetic stirrer bar. Chloroacetic chloride (0.40 mL, 5.02 mmol), was carefully added while stirring.
- the mixture was then split into two round bottle flasks (25 mL) and placed in an ultrasonic bath for 4 h. After removing the mixtures from the ultrasonic bath, they were quenched with NaHCO 3 and combined. The combined mixtures were extracted with ethyl acetate (20 mL x 3). The organic phases were combined and dried over Na 2 SO 4 , filtered and the solvent was removed under reduced pressure resulting in a dark thick oil with a yield of 69% (0.448 g, 1.54 mmol).
- Example 8 Synthesis of 2-Chloro-10-((1-methylpiperidin-2-yl)methyl)-10H- phenothiazine (Compounds EA09, EA10) 2-(Chloromethyl)-1-methylpiperidine (150 mg, 1.02 mmol) was dissolved in DMSO (4 mL), 2-chloro-10H-phenothiazine (240 mg, 1.02 mmol), KOH (170 mg, 3.05 mmol) and KI (a spatula tip) were added. The mixture was heated under reflux overnight.
- Example 10 Synthesis of 10-(2-(Piperidin-1-yl)ethyl)-10H-phenothiazine (Compound EA17) 10-(2-Chloroethyl)-10H-phenothiazine (0.165 g, 0.63 mmol) KI (0.222 g, 1.32 mmol), piperidine (0.28 ml, 2.85 mmol) and DMF (5 mL) were added to a 50 mL round bottle flask equipped with a magnetic stirrer. The mixture was heated to 100°C and stirred overnight. An NH 4 Cl solution (5 mL) was added and then extracted with ethyl acetate (10 mL x 3).
- Example 11 Synthesis of 10-(2-(Azepan-1-yl)ethyl)-10H-phenothiazine (Compound EA20) 10-(2-Chloroethyl)-10H-phenothiazine (0.206, 0.78 mmol), azepane (0.43 ml, 3.82 mmol), K 2 CO 3 (0.600 g, 4.34 mmol), KI (0.128, 0.77 mmol) and THF (20 mL) were added to a round bottle flask (100 mL) equipped with a condenser and a magnetic stirrer bar. The mixture was heated to reflux and stirred overnight.
- Compound EA20 10-(2-Chloroethyl)-10H-phenothiazine (0.206, 0.78 mmol), azepane (0.43 ml, 3.82 mmol), K 2 CO 3 (0.600 g, 4.34 mmol), KI (0.128, 0.77 mmol) and THF (20
- Example 12 Synthesis of N-(4-(10H-phenothiazin-10-yl)butyl)adamantan-1-amine (Compound EA22)
- EA22 Synthesis of 10-(4-chlorobutyl)-10H-phenothiazine: Phenothiazine (1.436 g, 7.21 mmol), anhydrous DMF (10 mL) and NaH (0.260 g, 10.8 mmol) were added to a dry round bottle flask (50 mL) equipped with a magnetic stirring bar. The flask was placed in an ice-water bath and 1-bromo-4- chlorobutane (0.82 ml, 7.11 mmol) was added to the flask.
- Example 13 Synthesis of N-(3-(10H-phenothiazin-10-yl)propyl)adamantan-1- amine (Compound EA23)
- EA23 Synthesis of 3-chloro-1-(10H-phenothiazin-10-yl)propan-1-one: 10H-phenothiazine (5.00 g, 25.09 mmol) and 80 ml toluene were added to a round bottle flask (500 mL) equipped with a magnetic stirring bar. The mixture was immersed into an ice-water bath and stirred before 3-chloropropanoyl chloride (3.60 mL, 37.64 mmol) was carefully added by syringe.
- the mixture was heated to 100°C and stirred for 24 h. 15 ml of a saturated aqueous solution of NH 4 Cl were added, in addition to 50 ml water before it was extracted with (50 ml x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO 4 . The organic extracts were filtered, and solvent removed in vacuo, to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate: hexane 9:1 and 1% Et 3 N), to obtain a brown waxy compound in a yield of 41% (0.401 g, 1.03 mmol).
- Example 14 Synthesis of N-(adamantan-1-yl)methyl)-2-(10H-phenothiazin-10- yl)ethan-1-amine
- Compound EA24 10-(2-Chloroethyl)-10H-phenothiazine (0.507 g, 1.94 mmol), KI (0.324 g, 1.95 mmol) 1-adamantanemethylamine (0.5 mL, 2.82 mmol) and DMF (10 ml) were added to a round bottle flask (50 mL) equipped with a magnetic stirrer bar. The mixture was then heated at 100°C and stirred for 24 h.
- Example 15 In vitro activity in cell lines Method: Cells from various cell lines (LN18, T98G, U87-MG, U251, NHA, SV80, P3XX) were seeded 20-24 h before the treatment in a 96-well plate to approximately 30% confluency and kept at 37°C in a humidified 5% CO 2 atmosphere.
- the glioblastoma cell lines U87-MG and U251 show reduced cell viability and proliferation assessed via percentage of confluency when treated with 4 ⁇ M EA01 compared to cells grown in media only (DMEM alt).
- the control cell line NHA (see Figure 1A) is not affected by treatment with 4 ⁇ M EA01.
- Temozolomide is not adding to the treatment effect of EA01 and EA02. Both compounds lead to reduced proliferation and cell death for the tested glioblastoma cell lines U87-MG and U251 in lower concentrations compared to normal human astrocytes (NHA) as control cell line.
- Example 16 - Cell Viability Assay Method The effect of the compounds EA01-EA10, EA16, EA17, EA20 and EA22 on the viability of various cell lines (LN18, T98G, U87-MG, U251, NHA, SV80, P3XX) was assessed using the WST-1 Assay (Roche, 11644807001).
- Cells were seeded at a concentration of 5000 cells ⁇ well -1 (or 10000 cells ⁇ well -1 for P3XX) in 96-well plates 20-24 h prior to treatment and kept at 37°C in a humidified 5% CO 2 atmosphere.
- the cells were treated with various concentrations of the compounds for 72 h before the WST-1 reagent was added in a 1:10 ratio dependent on the well media volume.
- a 30 second-shaking period on a linear shaker was followed by an incubation for 3 hours at 37°C.
- the proliferation rate was determined by measuring the absorbance at 450 nm with a microplate photometer (Multiskan FC, ThermoFisher Scientific).
- LC 50 values were determined for the different cell lines using the WST1 assay.
- Tumor spheroids of the stem-cell like cell lines P3, P3-GFP, BG5, BG5-GFP, BG7 and BG7-GFP were obtained by seeding 5000 cells per well in U-bottom 96-well plates. After centrifugation at 2000 rpm and 37°C for 90 min, cells were incubated at standard conditions. FRBO and tumor spheroids were treated with various concentrations of the compounds for 72 h before the WST-1 protocol was performed. Results: LC 50 values for treatment of the different primary glioblastoma cell lines derived from patient material are displayed in Table 2, with and without GFP-labelling. EA01 has a higher toxicity than EA02 in all studied stem-cell like cell lines.
- Example 19 Colony formation assay Method: LN18, U251 and NHA cells (125 cells per well) were seeded in 6-well culture plates in triplicate and incubated at 37°C in a humidified chamber of 5% CO 2 for up 14 days. Colonies were washed with PBS, fixed in methanol for 10 min and stained with crystal violet for 10 min at room temperature. Colonies were counted when they were formed by more than 50 cells. Results: As shown in Figure 5, the control cell line NHA tolerated higher concentrations of EA01 compared to the glioblastoma cell lines (LN18, LN229, U251).
Abstract
The invention provides compounds of formula (I), stereoisomers, and pharmaceutically acceptable salts thereof for use in the treatment of cancer: Formula (I) wherein: X is CH, S, N or NH; Z is C or N; A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2-groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR'- (where R' is H or C1-3 alkyl); each R1 is independently selected from: C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, -O-C1-6 alkyl, -S-C1-6 alkyl, -OH, -SH, halogen, and an optionally substituted aryl group; n is an integer from 0 to 4; R3 and R4 are each independently selected from: hydrogen, C2-6alkenyl, and C2-6 alkynyl, or R3 and R4, together with the intervening ring carbon atoms, form an optionally substituted aryl ring; and represents an optional bond between two adjacent carbon atoms in the ring. The compounds of formula (I), their stereoisomers and pharmaceutically acceptable salts find particular use in the treatment of glioblastoma.
Description
PHENOTHIAZINE ANTIPSYCHOTICS FOR USE IN THE TREATMENT OF
GLIOBLASTOMA
Field of the invention The present invention relates to compounds for use in the treatment of cancer, in particular for use in the treatment of glioblastoma. It further relates to certain novel compounds, to pharmaceutical compositions containing them, and to their use in such treatment. Background to the invention
The worldwide load of cancer has steadily risen over the years and the number of cancer cases is still increasing. Cancer represents a considerable cause of human suffering and early death and its treatment puts extensive pressure on global health economies.
Glioblastoma (also known as glioblastoma multiforme or “GBM”) is an incurable form of brain cancer. It is particularly difficult to treat due to its location and highly aggressive characteristics, however it can be treated for reiief and prolongation of life. Conventional treatment involves highly invasive (open brain) surgery, followed by radiation treatment and chemotherapy. Treatment may also involve Gamma Knife radiosurgery in which beams of radiation are highly focused on the tumour thereby minimising radiation damage to surrounding healthy tissues. Surgery is performed to remove as much of the tumour as possible, in high-risk areas of the brain, however, it may not be possible to remove all of the tumour by surgery alone. Radiotherapy is used to kill remaining tumour ceils after surgery and can also reduce tumour size, as well as the rate of tumour growth. However, radiotherapy does not have a major effect on tumours such as GBM due to its tendency to spread and the radio-resistance of the cancer cells. Furthermore, radiotherapy is not specific in destroying cancerous cells versus normal tissues. in addition to radiotherapy, chemotherapy may also be used although there are relatively few chemotherapeutics in clinical use for the treatment of GBM. Temozolomide and the nitrogen mustard β-chloro-nitrosourea carmustine, which are both alkylating agents, can be used as a first line treatment but these are mainly cytostatic as the cancer cells eventually develop resistance and render the
treatment no longer effective. Temozolomide is a prodrug which is activated by a first pass metabolic decomposition process in the liver that produces methyl diazonium ions which can penetrate the blood-brain barrier. Its mechanism of action involves alkylation of the guanine groups of DNA by the methyl diazonium ions. Despite current treatments, GBM is usually accompanied by recurrence with re- growth of tumours which requires repeated treatment. The poor prognosis of GBM is mainly due to the tumour’s high degree of invasiveness and the development of chemotherapy resistance. Tumours such as GBM thus remain particularly difficult to treat and existing therapies only offer a minimal increase in survival rates. The development of alternative treatments is urgently required, in particular treatments which have improved efficacy and which show high selectivity for the target cancer cells. Thioridazine (Mellaril) is a known antipsychotic drug belonging to the phenothiazine group of drugs. It has the following structure:
Thioridazine 10-[2-[(RS)-1-methylpiperidin-2-yl]ethyl]-2-methylsulfanyl-phenothiazine Thioridazine has primarily been used in the treatment of schizophrenia, but also for various psychiatric indications in patients with dementia. However, severe side- effects such as cardiac arrhythmias have been observed leading to its discontinued use. Its serious side-effects suggest that the agent possesses poor selectivity towards its drug target. In fact, Johannessen et al. (Int. J. Cancer 144: 1735-1745, 2019) recently discovered that thioridazine gives rise to inhibition of cellular autophagy. As a result, it has been investigated as a means to sensitize GBM cells to the chemotherapeutic agent temozolomide. Autophagy is a natural cellular
process that involves lysosome degradation in which cells capture unnecessary or dysfunctional intracellular components, such as proteins, lipids, and organelles, and deliver them to the lysosomal compartment where they are degraded. This effect has been observed in the context of cancer treatment, where the effect of the cytotoxic compound is minimized by degradation via the autophagy process. To date, however, there have been no reports of any cytotoxic effects associated with thioridazine or related phenothiazine compounds. The inventors have now found that certain compounds, in particular phenothiazine derivatives and related anthracene compounds, show high cytotoxicity and selectivity versus glioblastoma cells in in vitro tests in a range of glioblastoma cell lines. These compounds also have the advantage of high lipophilicity that will allow penetration across the blood-brain barrier. As a result of these findings, such compounds are proposed herein for use in the treatment of glioblastomas. In vitro tests conducted by the inventors in melanoma cell lines demonstrate the cytotoxicity of the compounds against other cancer cells. The inventor’s findings relating to the cytotoxic effects of the compounds herein described can thus be expected to extend to the treatment of other types of cancer. Summary of the invention In one aspect, the invention relates to a compound of formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer:
(I) wherein: X is CH, S, N or NH; Z is C or N;
A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2- groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl); each R1 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl); n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; R3 and R4 are each independently selected from: hydrogen, C2-6 alkenyl (preferably C2-4 alkenyl), and C2-6 alkynyl (preferably C2-4 alkynyl), or R3 and R4, together with the intervening ring carbon atoms, form an optionally substituted aryl ring (e.g. an optionally substituted phenyl ring); and represents an optional bond between two adjacent carbon atoms in the ring. In another aspect the invention relates to a compound of formula (Ia), (Ib) or (Ic) as herein described, a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer. In another aspect the invention relates to the use of a compound of formula (I), (Ia), (Ib) or (Ic), a stereoisomer, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer.
In another aspect, the invention relates to a method of treatment of cancer, said method comprising the step of administering to a subject in need thereof (e.g. a human patient) a pharmaceutically effective amount of a compound of formula (I), (Ia), (Ib) or (Ic), a stereoisomer, or a pharmaceutically acceptable salt thereof. In a further aspect, the invention relates to novel compounds of formula (II), their stereoisomers and their pharmaceutically acceptable salts:
(II) wherein: A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system, preferably an optionally substituted carbocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2- groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl); each R1 and R2 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl); n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; and
m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; with the proviso that the compound is other than thioridazine. In a further aspect, the invention relates to a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in therapy or for use as a medicament. In another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers, excipients or diluents. Detailed description of the invention Definitions As used herein, the term "alkyl" refers to a saturated hydrocarbon group and is intended to cover both straight-chained and branched alkyl groups. Examples of such groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, sec-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-methylbutyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. An alkyl group preferably contains from 1-6 carbon atoms, more preferably 1-4 carbon atoms, e.g.1-3 carbon atoms. Unless otherwise specified, any alkyl group may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different. Suitable substituents include -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br). As used herein, the term "alkenyl" refers to an alkyl group having one or more carbon-carbon double bonds and includes both straight-chained and branched alkenyl groups. The term "C2-6 alkenyl" refers to an alkenyl group having from 2 to 6 carbon atoms and one or more (e.g. one or two) double bonds. Examples of such groups include vinyl, allyl, propenyl, iso-propenyl, butenyl, iso-butenyl, crotyl, pentenyl and hexenyl. Unless otherwise stated, any alkenyl group mentioned herein may optionally be substituted by one or more groups, which may be identical or different. Suitable substituents include -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
As used herein, the term "alkynyl" refers to an alkyl group having one or more carbon-carbon triple bonds and includes both straight-chained and branched alkynyl groups. Unless otherwise stated, any alkynyl group mentioned herein may optionally be substituted by one or more groups, which may be identical or different. Suitable substituents include -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br). The term “carbocyclic ring system” as used herein refers to a monovalent, saturated or unsaturated cyclic carbon system. Such systems may include one or more carbon-containing rings. Where more than one ring is present the rings may be linked by a bond or they may be fused. Unless otherwise specified, any carbocyclic ring system may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different. Suitable substituents include -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br). The term “heterocyclic ring system” as used herein refers to a monovalent, saturated or unsaturated cyclic carbon system in which one or more carbon atoms are replaced by a heteroatom selected from oxygen, nitrogen or sulfur, preferably nitrogen. Such systems may include one or more rings in which at least one ring contains at least one heteroatom. Where more than one ring is present the rings may be linked by a bond or they may be fused. Unless otherwise specified, any heterocyclic ring system may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different. Suitable substituents include -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br). The term “cycloalkyl” refers to a monovalent, saturated cyclic carbon system. It includes monocyclic, bicyclic and polycyclic (e.g. tricyclic) rings. Monocyclic rings may contain from 3 to 8 carbon atoms, bicyclic rings may contain from 7 to 14 carbon atoms, and tricyclic rings may contain from 10 to 14 carbon atoms. Where these contain more than one ring, the rings may be fused or bridged. In fused compounds, two rings share two adjacent atoms. In bridged compounds, two rings share three or more atoms thereby forming a bridge which contains at least one
atom. Examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. Examples of bicyclic cycloalkyl groups include, but are not limited to, norbornyl. Examples of tricyclic cycloalkyl groups include, but are not limited to, adamantyl. Unless otherwise specified, any cycloalkyl group may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different. Suitable substituents include -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br). The term “cycloalkenyl” refers to a monovalent, partially unsaturated cyclic carbon system. It includes monocyclic, bicyclic and polycyclic (e.g. tricyclic) rings. Unless otherwise specified, any cycloalkenyl group may be substituted in one or more positions with a suitable substituent. Where more than one substituent group is present, these may be the same or different. Suitable substituents include -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br). As used herein, the term "alkylene" refers to a linking alkyl group and is intended to cover any straight-chained or branched alkylene group. Examples of such groups include methylene, ethylene, ethane-1,1-diyl, propylene, propane-2,2-diyl, 1- methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2- dimethylethylene, etc. Such groups may optionally be substituted by one or more groups selected from -O-C1-3 alkyl and halogen atoms (e.g. F, Cl or Br). The term “halogen” or “halogen atom” as used herein refers to -F, -Cl, -Br or -I. The term “haloalkyl” refers to an alkyl group as defined herein in which at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably F, Cl or Br. Examples of such groups include -CH2F, -CHF2, -CF3, -CCl3, -CHCl2, -CH2CF3, etc. The term “aryl” as used herein refers to aromatic ring systems. Such ring systems may be monocyclic or bicyclic and contain at least one unsaturated aromatic ring. Where these contain bicyclic rings, these may be fused. Preferably such systems contain from 6-20 carbon atoms, e.g. either 6 or 10 carbon atoms. Examples of such groups include phenyl, 1-napthyl and 2-napthyl. A preferred aryl group is
phenyl. Unless stated otherwise, any aryl group may be substituted by one or more substituents as described herein. Where more than one substituent group is present, these may be the same or different. The term “heterocyclic ring” as used herein refers to a saturated or partially unsaturated, 4- to 6-membered (preferably 5- or 6-membered) carbocyclic system in which at least one ring atom is a heteroatom selected from nitrogen, oxygen and sulfur, the remaining ring atoms being carbon. The heterocyclic ring structure may be linked to the remainder of the molecule through a carbon atom or through a nitrogen atom. Examples of heterocyclic rings include, but are not limited to, tetrahydrofuran, piperidine, pyrrolidine, dioxane, morpholine, etc. Unless otherwise stated, any heterocyclic ring mentioned herein may optionally be substituted by one or more groups, which may be identical or different, for example hydroxy, C1-6 alkyl, C1-6 alkoxy, amino, cyano, or nitro groups, or halogen atoms (e.g. F, Cl or Br). Unless otherwise stated, all substituents are independent of one another. In the case where a subscript is the integer 0 (i.e. zero), it is intended that the group to which the subscript refers is absent. The compounds herein described may contain one or more stereocenters and may therefore exist in different stereoisomeric forms. The term “stereoisomer” refers to compounds which have identical chemical constitution but which differ in respect of the spatial arrangement of the atoms or groups. Examples of stereoisomers are enantiomers and diastereomers. The term “enantiomers” refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. The term “diastereoisomers” refers to stereoisomers with two or more stereocenters which are not mirror images of one another. The invention is considered to extend to diastereomers and enantiomers, as well as racemic mixtures and enantioenriched mixtures in which the ratio of enantiomers is other than 1:1. The compounds herein described may be resolved into their enantiomers and/or diastereomers. For example, where these contain only one chiral center, these may be provided in the form of a racemate or racemic mixture (a 50:50 mixture of
enantiomers) or may be provided as pure enantiomers, i.e. in the R- or S-form. Any of the compounds which occur as racemates may be separated into their enantiomers by methods known in the art, such as column separation on chiral phases or by recrystallization from an optically active solvent. Those compounds with at least two asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallization, and where these compounds are obtained in racemic form, they may subsequently be resolved into their enantiomers. The term “pharmaceutically acceptable salt” as used herein refers to any pharmaceutically acceptable organic or inorganic salt of any of the compounds herein described. A pharmaceutically acceptable salt may include one or more additional molecules such as counter-ions. The counter-ions may be any organic or inorganic group which stabilises the charge on the parent compound. If the compound is a base, a suitable pharmaceutically acceptable salt may be prepared by reaction of the free base with an organic or inorganic acid. If the compound is an acid, a suitable pharmaceutically acceptable salt may be prepared by reaction of the free acid with an organic or inorganic base. Non-limiting examples of suitable salts are described herein. The term “pharmaceutically acceptable” means that the compound or composition is chemically and/or toxicologically compatible with other components of the formulation or with the patient to be treated. By “a pharmaceutical composition” is meant a composition in any form suitable to be used for a medical purpose. As used herein, the term "cancer" refers to cells undergoing abnormal proliferation. Growth of such cells typically causes the formation of a tumor. Cancerous cells may be benign, pre-malignant or malignant. Such cells may be invasive and/or have the ability to metastasize to other locations in the body. The term cancer, as used herein, includes cancerous growths, tumours, and their metastases. The term “tumour”, as used herein, refers to an abnormal mass of tissue containing cancerous cells.
As used herein, the term “metastasis” refers to the spread of malignant tumour cells from one organ or part of the body to another non-adjacent organ or part of the body. Cancer cells may break away from a primary tumour, enter the lymphatic and blood systems and circulate to other parts of the body (e.g. to normal tissues). Here they may settle and grow within the normal tissues. When tumour cells metastasize, the new tumours may be referred to as a “secondary” or metastatic cancer or tumour. As used herein, “treatment” includes any therapeutic application that can benefit a human or non-human animal (e.g. a non-human mammal). Both human and veterinary treatments are within the scope of the present invention, although primarily the invention is aimed at the treatment of humans. Where not explicitly stated, treatment encompasses prevention. As used herein, a “pharmaceutically effective amount” relates to an amount that will lead to the desired pharmacological and/or therapeutic effect, i.e. an amount of the agent which is effective to achieve its intended purpose. While individual subject (e.g. patient) needs may vary, determination of optimal ranges for effective amounts of the active agent(s) herein described is within the capability of one skilled in the art. Generally, the dosage regimen for treating a disease, condition or disorder with any of the compounds described herein may be selected by those skilled in the art in accordance with a variety of factors including the nature of the condition and its severity. The term “subject” refers to any individual who is the target of the administration or treatment. The subject may be, for example, a mammal. Thus the subject may be a human or non-human animal. The term “patient” refers to a subject under the treatment of a clinician. Preferably, the subject will be a human. In one aspect, the invention relates to a compound of formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer:
(I) wherein: X is CH, S, N or NH; Z is C or N; A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2- groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl); each R1 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl); n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; R3 and R4 are each independently selected from: hydrogen, C2-6 alkenyl (preferably C2-4 alkenyl), and C2-6 alkynyl (preferably C2-4 alkynyl), or
R3 and R4, together with the intervening ring carbon atoms, form an optionally substituted aryl ring (e.g. an optionally substituted phenyl ring); and represents an optional bond between two adjacent carbon atoms in the ring. In certain embodiments, the compounds for use according to the invention are those of formula (I) in which R3 and R4 are both hydrogen. In certain embodiments, the compounds for use according to the invention are those of formula (I) in which R3 and R4, together with the intervening ring carbon atoms, form an optionally substituted aryl group. In one embodiment, the aryl group which is formed can be an optionally substituted phenyl ring. Thus, in certain embodiments, the compounds for use according to the invention are those of formula (Ia), their stereoisomers, or pharmaceutically acceptable salts thereof:
(Ia) wherein X, Z, A, L, R1 and n are as herein defined; represents an optional bond between two adjacent carbon atoms in the ring; R2 is selected from any of the groups defined herein for R1; and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2. In one embodiment, the compounds for use according to the invention are those of formula (I) or (Ia) in which X is CH or S, preferably S. In one embodiment, the compounds for use according to the invention are those of formula (I) or (Ia) in which X is S and Z is N.
In certain embodiments, the compounds for use according to the invention are based on a phenothiazine scaffold. Such compounds are those of formula (Ib), their stereoisomers, or pharmaceutically acceptable salts thereof:
(Ib) wherein A, L, R1, R2, n and m are as herein defined. In one embodiment, the compounds for use according to the invention are those of formula (I) or (Ia) in which X is CH and Z is C. In certain embodiments, the compounds for use according to the invention are based on an anthracene scaffold. Such compounds are those of formula (Ic), their stereoisomers, and pharmaceutically acceptable salts thereof:
(Ic) wherein A, L, R1, R2, n and m are as herein defined. In any of the formulae herein defined, group A may be an optionally substituted amine. For example, group A may be a group of the formula -NRaRb wherein Ra and Rb are independently selected from H, optionally substituted C1-6 alkyl, and optionally substituted aryl. Examples of such groups include, but are not limited to, -NH2, -NH(CH3), -N(CH3)2, -N(CH3)(C2H5), and -N(C2H5)2. Alternatively, in any of the formulae herein defined, group A may be an optionally substituted carbocyclic or heterocyclic ring system. Such ring systems may
comprise from 3 to 14 ring atoms, preferably from 5 to 12 ring atoms, e.g. from 6 to 14 ring atoms. In one embodiment, group A is an optionally substituted carbocyclic ring system. In certain embodiments, group A may be an optionally substituted cycloalkyl or cycloalkenyl group. Such groups may be mono-, bi- or tricyclic. Where more than one ring is present, these may be bridged or fused. In one embodiment, A is a cycloalkyl group containing two or three rings which are fused or bridged. In one embodiment, A is an optionally substituted aryl group. For example, it may be an optionally substituted phenyl ring. In one embodiment, A is an optionally substituted heterocyclic group. Such groups may be mono-, bi- or poly-cyclic. Where more than one ring is present, these may be bridged or fused. Such groups may be saturated or unsaturated. Where these are saturated, they may be heteroaromatic. Non-limiting examples of group A include adamantyl, phenyl, quinuclidinyl (1- azabicyclo[2.2.2]octanyl), DABCO (1,4-diazabicyclo[2.2.2]octanyl), tropanyl (N- methyl-8-azabicyclo[3.2.1]octanyl), nortropanyl (8-azabicyclo[3.2.1]octanyl), norbornyl, norbornenyl, norbornadienyl, bornyl, pyrrolyl, pyrrolidinyl, piperidinyl, pyridinyl, morpholinyl, azepanyl (azacycloheptanyl), decahydroquinolyl, azonanyl, octahydrocyclopenta[c]pyrrolyl, azecanyl, octahydropyrrolo[3,4-c]pyrrolyl, indolyl, 4- t-butylpiperidinyl and azocanyl groups. In a preferred embodiment, group A is selected from substituted or unsubstituted adamantyl, phenyl, quinuclidinyl, piperidinyl and azepanyl. In another embodiment, group A is substituted or unsubstituted adamantyl or piperidinyl, preferably substituted or unsubstituted adamantyl. In one embodiment, group A is unsubstituted adamantyl.
Group A may be bonded to group L either through a ring carbon or ring nitrogen atom. In one embodiment, group A is bonded to the group L via a ring carbon atom. Group A may be substituted or unsubstituted. Where it is substituted, one or more substituent groups (e.g.1, 2, or 3 substituent groups) may be present on the ring. Each substituent may, independently of one another, be linked either to a ring carbon atom or to a ring nitrogen atom. In one embodiment, group A is substituted by one or more groups independently selected from -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br). Preferred substituents include, but are not limited to, methyl, ethyl, n-propyl and isopropyl groups. In one embodiment, group A is not substituted at any ring carbon atom. Where it is substituted, it is preferably substituted at a ring nitrogen. In another embodiment, group A is not substituted at any point on the ring, i.e. it is unsubstituted. The presence of a hydrogen atom on a ring nitrogen atom is not considered to be a “substituent”. Preferred examples of group A include the following (where denotes the point of attachment to the rest of the molecule):
Linking group L serves to link the group A to the remainder of the molecule. Group L may be an optionally substituted, straight-chained or branched C1-6 alkylene group. In one embodiment, L is an optionally substituted, straight-chained or branched C1-3 alkylene group.
In one embodiment, linking group L is an unsubstituted, straight-chained C1-6 alkylene group, preferably an unsubstituted, straight-chained C1-3 alkylene group, such as methylene or ethylene. In another embodiment, L may be an optionally substituted C1-6 alkylene group, preferably C2-6 alkylene group, in which one or more -CH2- groups of the alkylene chain are replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl). For example, L may be an optionally substituted C2-6 alkylene, C3-6 alkylene or C4-6 alkylene group in which one or more -CH2- groups of the alkylene chain are replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl). In one embodiment, the alkylene chain is straight-chained. In one embodiment, group L may be propylene or butylene in which one or two of the -CH2- groups are replaced by a group -NR’-, preferably by a group -NH- or -N(CH3)-. In another embodiment, group L may be pentylene in which one or two of the -CH2- groups are replaced by a group -NR’-, preferably by a group -NH- or -N(CH3)-. In one embodiment, one or more -CH2- groups of the alkylene chain in group L are replaced by a group -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl). In one embodiment, one or two -CH2- groups of the alkylene chain are replaced by such a group. Non-limiting examples of linking group L include the following (where denotes the point of attachment to the rest of the molecule):
Other examples of linking group L include the following (where denotes the point of attachment to the rest of the molecule):
Where present, substituent groups R1 and R2 may be the same or different. In one embodiment, each R1 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl). In one embodiment, each R1 is independently selected from C1-3 alkyl (e.g. -CH3), -CF3, -O-C1-3 alkyl (e.g. -OCH3 or -OCH2CH3), -S-C1-3 alkyl (e.g. -SCH3 or -SCH2CH3), F, Cl, Br and phenyl. In a preferred embodiment each R1 is independently selected from -CH3, -CF3, -OCH3, -SCH3, and -SCH2CH3. In one embodiment, n is selected from 0, 1 or 2, preferably 0 or 1. In one embodiment each R2, where present, is independently selected from C1-3 alkyl (e.g. -CH3), -CF3, -O-C1-3 alkyl (e.g. -OCH3 or -OCH2CH3), -S-C1-3 alkyl (e.g. -SCH3 or -SCH2CH3), F, Cl, Br and phenyl. In a preferred embodiment each R2 is independently selected from -CH3, -CF3, -OCH3, -SCH3, and -SCH2CH3. In one embodiment, m is selected from 0, 1 or 2, preferably 0 or 1. Examples of compounds for use in accordance with the invention include, but are not limited to, the following, their stereoisomers, and their pharmaceutically acceptable salts:
Certain compounds described herein are novel and these form a further aspect of the invention. Thus, in another aspect, the present invention provides compounds of formula (II), their stereoisomers and their pharmaceutically acceptable salts:
(II) wherein: A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2- groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl); each R1 and R2 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and
an optionally substituted aryl group (e.g. optionally substituted phenyl); n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; with the proviso that the compound is other than thioridazine. In one embodiment, the compound of formula (II) is other than 10-((1- methylpiperidin-2-yl)methyl)-2-(methylthio)-10H-phenothiazine or 10-(2-(piperidin-1- yl)ethyl)-10H-phenothiazine. Where appropriate, any of the definitions for A, L, R1, R2, n and m listed herein in respect of the compounds of formulae (I), (Ia), (Ib) and (Ic) similarly apply to the compounds of formula (II). In one embodiment, the invention provides compounds of formula (II), their stereoisomers and their pharmaceutically acceptable salts, in which A is an optionally substituted carbocyclic ring system. In one embodiment of formula (II), A is an optionally substituted cycloalkyl group, for example an optionally substituted cycloalkyl group containing two or three rings which are fused or bridged. In a particular embodiment of formula (II), A is substituted or unsubstituted adamantyl, for example unsubstituted adamantyl. In a further aspect, the invention relates to a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in therapy or for use as a medicament. In another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers, excipients or diluents. Any of the compounds herein described may be converted into a salt thereof, particularly into a pharmaceutically acceptable salt thereof with an inorganic or organic acid or base. Acids which may be used for this purpose include hydrochloric acid, hydrobromic acid, sulfuric acid, sulfonic acid, methane sulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric
acid, maleic acid, acetic acid, trifluoroacetic acid and ascorbic acid. Bases which may be suitable for this purpose include alkali and alkaline earth metal hydroxides, e.g. sodium hydroxide, potassium hydroxide or cesium hydroxide, ammonia and organic amines such as diethylamine, triethylamine, ethanolamine, diethanolamine, cyclohexylamine and dicyclohexylamine. Procedures for salt formation are conventional in the art. As will be understood, the compounds described herein may exist in various stereoisomeric forms, including enantiomers, diastereomers, and mixtures thereof. The invention encompasses all optical isomers of the compounds described herein and mixtures of optical isomers. Hence, compounds that exist as diastereomers, racemates and/or enantiomers are within the scope of the invention. The compounds for use in the invention are either known in the art, or can be prepared by methods known to those skilled in the art using readily available starting materials. Some of the compounds for use in the invention may be commercially available. Compounds herein described which are not known in the art may be prepared from readily available starting materials using synthetic methods known in the art such as those described in known textbooks, for example, in Advanced Organic Chemistry (March, Wiley Interscience, 5th Ed.2001) or Advanced Organic Chemistry (Carey and Sundberg, KA/PP, 4th Ed.2001). The following schemes illustrate general methods for preparing some of the compounds herein described. The compounds used as starting materials are either known from the literature or may be commercially available. As will be understood, other synthetic routes may be used to prepare the compounds using different starting materials, different reagents and/or different reaction conditions.
wherein R1, R2, A and n are as herein defined, and w is an integer from 0-5.
wherein R1, R2, R3, R4, A, L and n are as herein defined.
wherein R1, R2, R3, R4, A, L and n are as herein defined; and X is a halogen atom.
Cancers which may be treated in accordance with the invention include, but are not limited to, any of the following: leukemias, lymphomas, colon cancer (e.g. colorectal cancer), breast cancer, glioblastoma, pancreatic cancer, bladder cancer, lung cancer and skin cancer. Metastatic disease arising from any of these tumours may also be treated using any of the compounds herein described. However, the invention finds particular use in the treatment of deep lying cancerous lesions that are difficult to access non-invasively. Treatment of gliomas (e.g. GMB) forms a preferred aspect of the invention. The compounds described herein find use in the treatment of glioblastoma in a subject or patient and, in particular, in the treatment or prevention of astrocytomas, oligodendrogliomas or ependymomas. In a particular embodiment, the compounds described herein can be used in the treatment of astrocytomas, such as pliocytic astrocytoma, diffuse or low grade astrocytoma, anaplastic astrocytoma or grade 4 astrocytoma. The compounds described herein also find particular use in the treatment of skin cancers, for example in the treatment of basal cell carcinoma, squamous cell carcinoma, and melanoma. As used herein, a “subject” or “patient” encompasses any animal, preferably a mammal. Examples of mammalian subjects include, without limitation, humans, dogs, cats, rodents (e.g. mouse, rat, guinea pig, etc.), horses, cattle, sheep, and pigs. Preferably, the subject is a human. In one embodiment, the compounds of the invention are suitable for preventing and/or retarding cancer cell proliferation, differentiation and/or survival, or for preventing and/or retarding metastasis of cancer cells. As used herein, the term "proliferation" refers to cells undergoing mitosis. The term "retarding proliferation" indicates that the compounds inhibit proliferation of a cancer cell. In preferred embodiments, "retarding proliferation" indicates that DNA replication is at least 10% less than that observed in untreated cells, more preferably at least 25% less, yet more preferably at least 50% less, e.g.75%, 90% or 95% less than that observed in untreated cancer cells.
For use in a therapeutic treatment, the compounds herein described will typically be formulated as a pharmaceutical formulation together with one or more pharmaceutically acceptable carriers, excipients or diluents. Acceptable carriers, excipients and diluents for therapeutic use are well known in the art and can be selected with regard to the intended route of administration and standard pharmaceutical practice. Examples include binders, lubricants, suspending agents, coating agents, solubilizing agents, preserving agents, wetting agents, emulsifiers, surfactants, sweeteners, colorants, flavouring agents, antioxidants, odorants, buffers, stabilizing agents and/or salts. The compounds for use according to the invention may be formulated with one or more conventional carriers and/or excipients according to techniques well known in the art. Typically, the compositions will be adapted for oral or parenteral administration, for example by intradermal, subcutaneous, intraperitoneal, or intravenous injection. For example, these may be formulated in conventional oral administration forms, e.g. tablets, coated tablets, caplets, capsules, powders, granulates, solutions, dispersions, suspensions, syrups, emulsions, etc. using conventional excipients, e.g. solvents, diluents, binders, sweeteners, aromas, pH modifiers, viscosity modifiers, antioxidants, etc. Suitable excipients can readily be determined by those skilled in the art. The formulations may be prepared using conventional techniques, such as dissolution and/or mixing procedures. Where parenteral administration is employed this may, for example, be by means of intravenous, subcutaneous, intraperitoneal or intramuscular injection. For this purpose, sterile solutions containing the active agent may be employed, such as an oil-in-water emulsion. Where water is present, an appropriate buffer system (e.g., sodium phosphate, sodium acetate or sodium borate) may be added to prevent pH drift under storage conditions. The use of orally administrable compositions, e.g. tablets, coated tablets, capsules, syrups, etc. is preferred. Compounds having a partition coefficient, Log P, greater than or equal to 3 and less than or equal to 5 are particularly suitable for oral administration due to their ability to cross the blood brain barrier.
Alternatively, any pharmaceutical formulation may be administered locally (e.g. by injection or topically) at or near the affected site. Topical pharmaceutical formulations include gels, creams, ointments, sprays, lotions, salves, sticks, powders, solutions and any of the other conventional pharmaceutical forms in the art. Ointments, gels and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Any thickening or gelling agents used should be non-toxic and non-irritant. Lotions may be formulated with an aqueous or oily base and will, in general, also contain one or more emulsifying, dispersing, suspending, thickening or colouring agents. Powders may be formed with the aid of any suitable powder base. Sprays and solutions may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing, solubilising or suspending agents. The formulations herein described may be prepared using conventional techniques, such as dissolution and/or mixing procedures, tableting, etc. The dosage required to achieve the desired activity of the compounds herein described will depend on various factors, such as the compound selected, its mode and frequency of administration, whether the treatment is therapeutic or prophylactic, and the nature and severity of the disease or condition, etc. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon factors such as the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age of the patient, the mode and time of administration, and the severity of the particular condition. The compound and/or the pharmaceutical composition may be administered in accordance with a regimen from 1 to 10 times per day, such as once or twice per day. For oral and parenteral administration to human patients, the daily dosage level of the agent may be in single or divided doses. Suitable daily dosages of the compounds herein described may readily be determined by those skilled in the art, but are expected to be in the range from 0.1 mg to 1 g of the compound; 1 mg to 500 mg of the compound; 1 mg to 300 mg of
the compound; 5 mg to 100 mg of the compound, or 10 mg to 50 mg of the compound. By a “daily dosage” is meant the dosage per 24 hours. Embodiments of the invention include, but are not limited to, the following: Embodiment 1: A compound of formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer:
(I) wherein: X is CH, S, N or NH; Z is C or N; A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2- groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl); each R1 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and
an optionally substituted aryl group (e.g. optionally substituted phenyl); n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; R3 and R4 are each independently selected from: hydrogen C2-6 alkenyl (preferably C2-4 alkenyl), and C2-6 alkynyl (preferably C2-4 alkynyl), or R3 and R4, together with the intervening ring carbon atoms, form an optionally substituted aryl ring (e.g. an optionally substituted phenyl ring); and represents an optional bond between two adjacent carbon atoms in the ring. Embodiment 2: A compound for use as described in embodiment 1, wherein R3 and R4, together with the intervening ring carbon atoms, form an optionally substituted aryl group. Embodiment 3: A compound for use as described in embodiment 1 or embodiment 2 which is a compound of formula (Ia), a stereoisomer, or a pharmaceutically acceptable salt thereof:
(Ia) wherein X, Z, A, L, R1 and n are as defined in embodiment 1; represents an optional bond between two adjacent carbon atoms in the ring; each R2 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3),
-OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl); and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2. Embodiment 4: A compound for use as described in any one of embodiments 1 to 3, wherein X is CH or S, preferably S. Embodiment 5: A compound for use as described in embodiment 4 which is a compound of formula (Ib), a stereoisomer, or a pharmaceutically acceptable salt thereof:
wherein A, L, R1 and n are as defined in embodiment 1; and R2 and m are as defined in embodiment 3. Embodiment 6: A compound for use as described in any one of embodiments 1 to 3 which is a compound of formula (Ic), a stereoisomer, or a pharmaceutically acceptable salt thereof:
wherein A, L, R1 and n are as defined in embodiment 1; and R2 and m are as defined in embodiment 3.
Embodiment 7: A compound for use as described in any one of embodiments 1 to 6, wherein A is an optionally substituted carbocyclic or heterocyclic ring system. Embodiment 8: A compound for use as described in embodiment 7, wherein A is an optionally substituted cycloalkyl or cycloalkenyl group, preferably an optionally substituted cycloalkyl group containing two or three rings which are fused or bridged. Embodiment 9: A compound for use as described in embodiment 7, wherein A is an optionally substituted heterocyclic group. Embodiment 10: A compound for use as described in embodiment 8 or embodiment 9, wherein A is selected from substituted or unsubstituted adamantyl, phenyl, quinuclidinyl, piperidinyl and azepanyl. Embodiment 11: A compound for use as described in any one of embodiments 1 to 10, wherein A is substituted by one or more groups independently selected from -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br). Embodiment 12: A compound for use as described in any one of embodiments 1 to 11, wherein A is selected from the following:
. Embodiment 13: A compound for use as described in any one of embodiments 1 to 12, wherein L is an optionally substituted, straight-chained or branched C1-6 alkylene group.
Embodiment 14: A compound for use as described in any one of embodiments 1 to 12, wherein L is an optionally substituted C1-6 alkylene group, preferably C2-6
alkylene group, in which one or more -CH2- groups of the alkylene chain are replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl). Embodiment 15: A compound for use as described in any one of embodiments 1 to 14, wherein L is selected from the following:
Embodiment 16: A compound for use as described in any one of embodiments 1 to 15, wherein each R1 is independently selected from C1-3 alkyl (e.g. -CH3), -CF3, -O- C1-3 alkyl (e.g. -OCH3 or -OCH2CH3), -S-C1-3 alkyl (e.g. -SCH3 or -SCH2CH3), F, Cl, Br and phenyl. Embodiment 17: A compound for use as described in any one of embodiments 1 to 16, wherein n is 0, 1 or 2, preferably 0 or 1. Embodiment 18: A compound for use as described in any one of embodiments 3 to 17, wherein each R2 is independently selected from C1-3 alkyl (e.g. -CH3), -CF3, -O- C1-3 alkyl (e.g. -OCH3 or -OCH2CH3), -S-C1-3 alkyl (e.g. -SCH3 or -SCH2CH3), F, Cl, Br and phenyl. Embodiment 19: A compound for use as described in any one of embodiments 3 to 18, wherein m is 0, 1 or 2, preferably 0 or 1.
Embodiment 20: A compound for use as described in embodiment 1 which is selected from the following compounds, their stereoisomers, and their pharmaceutically acceptable salts:
Embodiment 21: A compound for use as described in any one of embodiments 1 to 20, wherein said cancer is selected from the group consisting of: leukemias, lymphomas, colon cancer, breast cancer, glioblastoma, pancreatic cancer, bladder cancer, lung cancer and skin cancer. Embodiment 22: A compound for use as described in embodiment 21 in the treatment of glioblastoma, preferably in the treatment of an astrocytoma, oligodendroglioma or ependymoma. Embodiment 23: A compound for use as described in embodiment 21 in the treatment of basal cell carcinoma, squamous cell carcinoma, or melanoma. Embodiment 24: A compound of formula II, a stereoisomer or a pharmaceutically acceptable salt thereof:
(II) wherein: A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2- groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl);
each R1 and R2 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl); n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; with the proviso that the compound is other than thioridazine. Embodiment 25: A pharmaceutical composition comprising a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof as described in embodiment 24, together with one or more pharmaceutically acceptable carriers, excipients or diluents. The invention will now be described in more detail in the following non-limiting Examples and with reference to the accompanying figures: Figure 1: Monitoring cell growth and morphology during treatment with 4 µM Compound EA01 after treatment for 72 h. (A) Left: Normal Human Astrocytes (NHA) (DMEM alt), right: NHA with 4 µM Compound EA01. (B) Left: U87-MG Control (DMEM alt), right: U87-MG with 4 µM Compound EA01. (C) Left: U251 Control (DMEM alt), right: U251 with 4 µM Compound EA01. Figure 2: IncuCyte Zoom Analysis of U87-MG, p44-46, n=3 for various treatment conditions of Compounds EA01 and EA02 with and without combination with temozolomide (TMZ), normalized to the confluency [%] to time point 0 h. (A) Monitored change fold of confluency (confluency of each time point normalised to the confluency of t=0 h) for U87-MG, p44-46 over 72 h. Shown are means of the measured confluency [%]. (B) 72 h values of change fold confluency. Statistical
analysis was carried out using Dunnett's multiple comparisons test (Ordinary One- Way ANOVA, parametric): Significant results are indicated by asterisks: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Whiskers indicate SEM. Figure 3: Cell viability assessed via WST1-assay of two generations of FRBO treated with Compounds EA01 and EA02 for 72 h (n=2). (A) Cell viability curve for FRBO treated with Compound EA01. (B) Cell viability curve for FRBO treated with Compound EA01. Figure 4: Treatment of tumor spheroids and fetal rat brain organoids (FRBO) with Compounds EA01 and EA02. (A) Co-culture pf P3-GFP tumor spheroids with FRBO after 72 h-treatment with indicated concentrations of Compounds EA01 and EA02. (B) Co-culture pf BG5-GFP tumor spheroids with FRBO after 72 h-treatment with indicated concentrations of Compounds EA01 and EA02. Figure 5: Initial testing of survivability of different cell lines after treatment with 4 µM Compounds EA01 and EA02 versus control (0.1 % DMSO) using the clonogenic assay. (n=1). Examples General procedure for synthesis of phenothiazine derivatives: The synthesis of the various phenothiazine derivatives was conducted by means of a three-step synthetic pathway. In the following reaction schemes, A, R1, R2, n and m are as herein defined. Step 1 – method A:
The 10H-phenothiazine derivative (1 eq.) 1 was treated with chloroacetyl chloride (2.7 eq.) 2 under microwave irradiation. When the microwave reaction was finished, water was added and the mixture was extracted with ethyl acetate, the extracts were combined and washed with brine. The organic layer was dried over Na2SO4, filtered, and the solvent removed in vacuo. The compound 3 was purified by recrystallization in methanol. Step 1 – method B:
The 10H-phenothiazine derivative (1 eq.) 1 and toluene were added to a round bottle flask equipped with a magnetic stirring bar. The mixture was then placed in an ice-water bath and stirred while chloroacetyl chloride (1.5 eq.) 2 was carefully added by a syringe. The mixture was heated and left stirring. The mixture was then cooled to room temperature and the solvent was removed in vacuo. The compound 3 was then purified by recrystallization in methanol. Step 2:
The 2-chloro-1-(10H-phenothiazin-10-yl)ethan-1-one derivative (1 eq.) 3 and dry THF were added to a dry round bottle flask equipped with a magnetic stirring bar. The mixture was flushed with nitrogen, put in an ice water bath and BF3•Et2O (1.5 eq.) carefully added by syringe while stirring. NaBH4 (1.2 eq.) was added and the mixture was stirred before it was put in an ultrasonic bath. After removing the
mixture from the ultrasonic bath, it was quenched with NaHCO3 and extracted with ethyl acetate. The organic phases were combined and dried over Na2SO4, filtered, and the solvent was removed in vacuo. Step 3 – method A:
The 10-(2-chloroethyl)-10H-phenothiazine derivative (1 eq.) 4, KI (1 eq.), amine (5 eq.) and DMF were added to a round bottle flask equipped with a magnetic stirrer. The mixture was heated and left stirring. When the reaction was finished it was cooled to room temperature and an aqueous solution of NH4Cl was added, before it was extracted with ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were filtered, and the solvent removed in vacuo. The compound 5 was purified using flash column chromatography. Step 3 – method B:
The 10-(2-chloroethyl)-10H-phenothiazine derivative (1 eq.) 4, amine (5 eq.), K2CO3 (5.5 eq.), KI (1 eq.) and THF were added to a round bottle flask equipped with a condenser and a magnetic stirrer. The mixture was heated to reflux and stirred. When the reaction was finished it was cooled to room temperature and water added before it was extracted with ethyl acetate. The organic extracts were dried over
Na2SO4, filtered and the solvent was removed in vacuo. The compound 5 was purified using flash column chromatography. Example 1 - Synthesis of N-(2-(10H-Phenothiazin-10-yl)ethyl)adamantan-1-amine (Compound EA01)
Synthesis of 2-chloro-1-(10H-phenothiazin-10-yl)ethan-1-one: 10H-phenothiazine (0.373 g, 1.87 mmol) and 5 mL of chlorobenzene were added to a microwave vial (20 mL) together with a magnetic stirrer bar. Chloroacetic chloride (0.40 mL, 5.02 mmol), was carefully added while stirring. After addition of chloroacetic chloride the mixture was capped and put in the microwave for 30 min at 120°C (in addition to 10 min of pre-stirring). When the reaction in the microwave was completed, water (5 mL) was added. The mixture was extracted with ethyl acetate (10 mL x 3), the extracts were combined and washed with brine. The organic layer was dried over Na2SO4, filtered, and the solvent removed under reduced pressure. The compound was recrystallized in methanol resulting in white crystals with a yield of 93% (0.479 g, 1.74 mmol). Synthesis of 2-chloro-1-(10H-phenothiazin-10-yl)ethan-1-one: 10H-phenothiazine (5.00 g, 25.09 mmol) and 75 mL toluene were added to a 500 mL round bottle flask equipped with a magnetic stirring bar. The mixture was then placed in an ice-water bath and stirred before chloroacetyl chloride (3 mL, 37.67 mmol) was carefully added by a syringe. The mixture was heated at 80°C and stirred for 20 h. The mixture was then cooled at room temperature and the solvent was removed under reduced pressure. The compound was then purified by recrystallization in methanol to afford white crystals in a yield of 64% (4.400 g, 15.96 mmol).
1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 7.9 Hz, 2H), 7.40 (d, J = 7.7 Hz, 2H), 7.29 (t, J = 7.7 Hz, 2H), 7.20 (t, J = 6.7 Hz, 2H), 4.12 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 166.07, 137.90, 128.18, 127.45, 127.36, 126.60, 42.72. Synthesis of 10-(2-chloroethyl)-10H-phenothiazine: 2-Chloro-1-(10H-phenothiazin-10-yl)ethan-1-one (0.181 g, 0.65 mmol) and dry THF (5 mL) were added to a dry 25 mL round bottle flask equipped with a magnetic stirring bar. The mixture was flushed with nitrogen and put in an ice water bath and BF3•Et2O (0.15 mL, 1.22 mmol) carefully added by syringe while stirring. NaBH4 (0.026 g, 0.69 mmol) was added and the mixture was stirred for 1 h. The mixture was then put in an ultrasonic bath for 2 h. After removing the mixture from the ultrasonic bath, it was quenched with NaHCO3 and then extracted with ethyl acetate (10 mL x 3). The organic phases were combined and dried over Na2SO4, filtered, and solvent was removed under reduced pressure to provide a white solid in a yield of 89% (0.153 g, 0.58 mmol). 1H NMR (500 MHz, CDCl3) δ 7.12 – 7.06 (m, 4H), 6.87 (td, J = 7.5, 1.1 Hz, 2H), 6.80 (d, J = 8.1 Hz, 2H), 4.18 – 4.13 (m, 2H), 3.74 – 3.69 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 144.35, 127.73, 127.48, 125.39, 123.11, 115.20, 49.24, 39.93. Synthesis of N-(2-(10H-Phenothiazin-10-yl)ethyl)adamantan-1-amine EA01: 10-(2-Chloroethyl)-10H-phenothiazine (0.172 g, 0.66 mmol), a spatula tip of KI, adamantylamine (0.466 g, 3.08 mmol) and DMF (10 mL) were added to a 50 mL round bottle flask equipped with a magnetic stirrer. The mixture was heated to 100°C and stirred for 24 h. A NH4Cl solution (10 mL) was then added, before it was extracted with (20 mL x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were then filtered and dried under reduced pressure to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate: hexane 9:1 and 1% Et3N), to obtain a purple waxy compound in the yield of 44% (0.110 g, 0.29 mmol). Rf = 0.36 (ethyl acetate: hexane 9:1). 1H NMR (500 MHz, CDCl3) δ 7.15 (ddd, J = 7.5, 6.3, 1.7 Hz, 4H), 6.95 – 6.90 (m, 4H), 4.04 (t, J = 6.4 Hz, 2H), 2.98 (t, J = 6.4 Hz, 2H), 2.00 (s, 3H), 1.62 (d, J = 12.4 Hz, 4H), 1.52 (d, J = 2.9 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 145.11, 127.53, 127.30, 125.71, 122.73, 115.88, 50.83, 47.82, 42.31, 37.27, 36.58, 29.49.
Example 2 - Synthesis of N-(2-(2-(trifluoromethyl)-10H-phenothiazin-10- yl)ethyl)adamantan-1-amine (Compound EA02)
Synthesis of 2-Chloro-1-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)ethan-1-one: 2-Trifluormethyl-10H-phenothiazine (0.501 g, 1.87 mmol) and 5 mL of chlorobenzene were added to a 20 mL microwave vial together with a magnetic stirring bar. Chloroacetic chloride (0.4 mL, 5.02 mmol) was carefully added while stirring. After addition of chloroacetic chloride the mixture was capped and put in the microwave for 30 min at 120°C (in addition to 10 min of pre-stirring). When the reaction in the microwave was completed 5 mL of water was added. The mixture was extracted with ethyl acetate (10 mL x 3), the extracts were combined and washed with brine. The organic layer was dried over Na2SO4, filtered and the solvent removed under reduced pressure. The compound was recrystallized in methanol resulting in light green crystals in a yield of 95% (0.615 g, 1.79 mmol). Synthesis of 2-Chloro-1-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)ethan-1-one: 2-Trifluormethyl-10H-phenothiazine (6.701 g, 25.07 mmol) and 75 mL toluene were added to a 500 mL round bottle flask equipped with a magnetic stirring bar. The mixture was put in an ice water bath and stirred before chloroacetic chloride (3.00 mL, 37.67 mmol) was carefully added by syringe. The mixture was heated to 80°C and left stirring for 20 h. The mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The compound was then purified by recrystallization in methanol, resulting in light green crystals in a yield of 87% (7.504 g, 21.82 mmol). 1H NMR (500 MHz, DMSO) δ 8.07 (s, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.72 (dd, J = 20.7, 8.1 Hz, 2H), 7.63 (d, J = 7.8 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.39 (t, J = 7.7 Hz, 1H), 4.56 (d, J = 33.2 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 165.12, 137.87, 137.67, 136.82, 131.31, 128.97, 128.25, 128.03, 127.88, 126.83, 124.00, 123.78, 42.68, 39.50.
Synthesis of 10-(2-Chloroethyl)-2-(trifluoromethyl)-10H-phenothiazine: 2-Chloro-1-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)ethan-1-one (0.340 g, 0.99 mmol) and dry THF (5 mL) were added to a dry 50 mL round bottle flask equipped with a magnetic stirring bar. The mixture was flushed with nitrogen and put in an ice water bath and BF3•Et2O (0.18 mL, 1.46 mmol) carefully added by syringe while stirring. NaBH4 (0.044 g, 1.16 mmol) was added and the mixture was stirred for 1 h. The mixture was then put in an ultrasonic bath for 2 h. After removing the mixture from the ultrasonic bath, it was quenched with NaHCO3 and then extracted with ethyl acetate (20 mL x 3). The organic phases were combined and dried over Na2SO4, filtered and solvent was removed under reduced pressure resulting in a white solid, and obtaining a yield of 87% (0.284 g, 0.86 mmol). 1H NMR (500 MHz, CDCl3) δ 7.24 – 7.17 (m, 3H), 7.15 (dd, J = 7.7, 1.5 Hz, 1H), 7.03 (s, 1H), 6.99 (td, J = 7.5, 1.2 Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 4.25 (t, J = 7.1 Hz, 2H), 3.81 – 3.76 (t, J = 7.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 144.98, 143.44, 127.89, 127.82, 124.64, 123.77, 119.79, 119.76, 115.64, 111.76, 49.37, 39.72. Synthesis of N-(2-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)ethyl)adamantan-1- amine EA02: 10-(2-Chloroethyl)-2-(trifluoromethyl)-10H-phenothiazine (0.205 g, 0.62 mmol), KI (0.137 g, 0.82 mmol), adamantylamine (0.459 g, 3.03 mmol) and DMF (5 mL) were added to a round bottle flask (25 mL) equipped with a magnetic stirrer bar. The mixture was heated to 100°C and stirred for 24 h. An NH4Cl solution (5 mL) was then added, before it was extracted with (10 mL x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were then filtered and the solvent was removed under reduced pressure, to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate: hexane 9:1 and 1% Et3N) which resulted in a waxy compound with a yield of 31% (0.085 g, 0.19 mmol). Rf = 0.29 (ethyl acetate: hexane 9:1). 1H NMR (500 MHz, CDCl3) δ 7.14 – 7.02 (m, 5H), 6.90 – 6.81 (m, 2H), 3.93 (t, J = 6.4 Hz, 2H), 2.88 (t, J = 6.4 Hz, 2H), 1.92 (s, 3H), 1.54 (d, J = 12.4 Hz, 3H), 1.49 – 1.37 (m, 9H).13C NMR (126 MHz, CDCl3) δ 145.67, 144.19, 127.67, 127.61,
127.48, 124.51, 123.31, 119.27, 116.15, 112.42, 50.33, 48.59, 42.61, 37.14, 36.64, 29.52. Example 3 - Synthesis of N-(2-(2-Chloro-10H-phenothiazin-10-yl)ethyl)adamantan- 1-amine (Compound EA04)
Synthesis of 2-Chloro-1-(2-chloro-10H-phenothiazin-10-yl)ethan-1-one: 2-Chloro-10H-phenothiazine (0.302 g, 1.29 mmol) and 5 mL of chlorobenzene were added to a 20 mL microwave vial together with a magnetic stirring bar. Chloroacetic chloride (0.28 mL, 3.52 mmol) was carefully added while stirring. After addition of chloroacetic chloride the mixture was capped and put in the microwave for 30 min at 120°C (in addition to 10 min of pre-stirring). When the reaction in the microwave was completed, 5 mL of water was added. The mixture was extracted with ethyl acetate (10 mL x 3), the extracts were combined and washed with brine. The organic layer was dried over Na2SO4, filtered and the solvent removed under reduced pressure. The compound was recrystallized in methanol resulting in light green crystals in a yield of 91% (0.366 g, 1.18 mmol). 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 2.2 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.47 (dd, J = 7.8, 1.5 Hz, 1H), 7.40 – 7.35 (m, 2H), 7.30 (td, J = 7.6, 1.4 Hz, 1H), 7.27 – 7.24 (m, 1H), 4.26 – 4.15 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 171.40, 165.77, 138.77, 137.37, 128.66, 128.38, 127.85, 127.71, 127.63, 127.07, 126.32, 40.55. Synthesis of 2-Chloro-10-(2-chloroethyl)-10H-phenothiazine: 2-Chloro-1-(2-chloro-10H-phenothiazin-10-yl)ethan-1-one (0.303 g, 0.98 mmol) and dry THF (5 mL) were added to a dry 25 mL round bottle flask equipped with a magnetic stirring bar. The mixture was flushed with nitrogen and put in an ice water bath and BF3•Et2O (0.2 mL, 1.62 mmol) carefully added by syringe while stirring. NaBH4 (0.051 g, 1.35 mmol) was added and the mixture was stirred for a few min. The mixture was then put in an ultrasonic bath for 2 h. The mixture was removed
from the ultrasonic bath and quenched with NaHCO3 and then extracted with ethyl acetate (10 mL x 3). The organic phases were combined and dried over Na2SO4, filtered, and solvent was removed under reduced pressure resulting in a light pink solid in a yield of 84% (0.244 g, 0.82 mmol. 1H NMR (500 MHz, CDCl3) δ 7.12 – 7.03 (m, 2H), 6.94 (d, J = 8.1 Hz, 1H), 6.88 (t, J = 7.5 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 6.77 (d, J = 8.1 Hz, 1H), 6.74 (s, 1H), 4.09 (t, J = 7.2 Hz, 2H), 3.68 (t, J = 7.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 145.76, 143.70, 133.50, 128.30, 127.90, 127.76, 125.30, 124.04, 123.64, 123.05, 115.74, 115.60, 77.16, 49.36, 39.85. Synthesis of N-(2-(2-Chloro-10H-phenothiazin-10-yl)ethyl)adamantan-1-amine EA04: 2-Chloro-10-(2-chloroethyl)-10H-phenothiazine (0.505 g, 1.23 mmol), KI (0.365 g, 2.19 mmol), adamantylamine (1.282 g, 8.48 mmol) and DMF (10 mL) were added to a round bottle flask (50 mL) equipped with a magnetic stirrer bar. The mixture was heated at 100°C and stirred for 24 h. An NH4Cl solution (10 mL) was then added, before it was extracted with (20 mL x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were then filtered, and solvent removed under reduced pressure to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acate : hexane = 9:1 and 1% Et3N) and resulted in a waxy compound in a yield of 32% (0.161 g, 0.39 mmol). 1H NMR (500 MHz, CDCl3) δ 7.15 (ddd, J = 14.7, 7.4, 1.5 Hz, 2H), 7.03 (d, J = 8.0 Hz, 1H), 6.94 (td, J = 7.5, 1.2 Hz, 1H), 6.92 – 6.87 (m, 3H), 3.97 (t, J = 6.4 Hz, 2H), 2.95 (t, J = 6.4 Hz, 2H), 2.00 (s, 3H), 1.62 (d, J = 12.2 Hz, 3H), 1.58 – 1.50 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 146.44, 144.39, 133.30, 127.94, 127.57, 127.47, 125.29, 124.03, 123.13, 122.51, 116.12, 50.51, 48.38, 42.54, 37.22, 36.63, 29.51.
Example 4 - Synthesis of N-(2-(2-Methoxy-10H-phenothiazin-10-yl)ethyl) adamantan-1-amine (Compound EA05)
Synthesis of 2-Chloro-1-(2-methoxy-10H-phenothiazin-10-yl)ethan-1-one: 2-Methoxy-10H-phenothiazine (0.608 g, 2.65 mmol) and chlorobenzene (10 mL) were added to a microwave vial (20 mL) together with a magnetic stirring bar. Chloroacetic chloride (0.55 mL, 6.91 mmol) was carefully added while stirring. After the addition of chloroacetic chloride the mixture was capped and put in the microwave for 30 min at 120°C (in addition to 5 min of pre-stirring). When the reaction in the microwave was completed 10 mL of water was added. The mixture as extracted with ethyl acetate (20 mL x 3), the extracts were combined and washed with brine. The organic layer was dried over Na2SO4, filtered and the solvent removed under reduced pressure. The compound was recrystallized in methanol resulting in light yellow crystals with a yield of 87% (0.706 g, 2.30 mmol). 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 7.9 Hz, 1H), 7.46 (dd, J = 7.8, 1.5 Hz, 1H), 7.34 (t, J = 8.5 Hz, 2H), 7.28 – 7.24 (m, 2H), 7.19 (d, J = 2.7 Hz, 1H), 6.85 (dd, J = 8.7, 2.7 Hz, 1H), 4.20 (s, 2H), 3.83 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.52, 159.34, 139.15, 137.90, 128.58, 128.15, 127.40, 127.18, 114.08, 55.77, 41.83. Synthesis of 10-(2-Chloroethyl)-2-methoxy-10H-phenothiazine: 2-Chloro-1-(2-methoxy-10H-phenothiazin-10-yl)ethan-1-one (0.688 g, 2.24 mmol) and dry THF (16 mL) were added to a dry round bottle flask (50 mL) equipped with a magnetic stirrer bar. The mixture was flushed with nitrogen and put on an ice water bath and BF3•Et2O (0.50 mL, 4.05 mmol) carefully added by syringe while stirring. NaBH4 (0.109 g, 2.88 mmol) was added and the mixture was stirred for a 1 h. The mixture was then split into two round bottle flasks (25 mL) and placed in an ultrasonic bath for 4 h. After removing the mixtures from the ultrasonic bath, they were quenched with NaHCO3 and combined. The combined mixtures were extracted with ethyl acetate (20 mL x 3). The organic phases were combined and
dried over Na2SO4, filtered and the solvent was removed under reduced pressure resulting in a dark thick oil with a yield of 69% (0.448 g, 1.54 mmol). 1H NMR (500 MHz, CDCl3) δ 7.02 (ddd, J = 7.3, 6.0, 1.6 Hz, 2H), 6.90 (d, J = 8.4 Hz, 1H), 6.81 (td, J = 7.4, 1.2 Hz, 1H), 6.71 (d, J = 8.5 Hz, 1H), 6.38 (dd, J = 8.4, 2.5 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 4.07 – 4.03 (m, 2H), 3.68 – 3.63 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 159.92, 145.75, 144.16, 128.01, 127.69, 127.37, 125.92, 123.13, 116.18, 115.31, 103.22, 55.58, 49.30, 39.99. Synthesis of N-(2-(2-Methoxy-10H-phenothiazin-10-yl)ethyl)adamantan-1-amine EA05: 10-(2-Chloroethyl)-2-methoxy-10H-phenothiazine (0.448 g, 1.53 mmol), KI (0.263 g, 1.58 mmol), adamantylamine (1.171 g, 7.74 mmol) and DMF (8 mL) were added to a round bottle flask (50 mL) equipped with a magnetic stirrer bar. The mixture was heated at 100°C and stirred for 24 h. An NH4Cl solution (10 mL) was then added, before it was extracted with (20 mL x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were then filtered and dried under reduced pressure to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate: hexane = 9:1 and 1% Et3N) obtaining a waxy blue compound with a yield of 15% (0.092 g, 0.22 mmol). 1H NMR (500 MHz, CDCl3) δ 7.16 – 7.10 (m, 2H), 7.03 (d, J = 8.3 Hz, 1H), 6.91 (t, J = 7.1 Hz, 2H), 6.53 – 6.47 (m, 2H), 4.00 (t, J = 6.4 Hz, 2H), 3.76 (s, 3H), 2.97 (t, J = 6.4 Hz, 2H), 2.00 (s, 3H), 1.61 (d, J = 12.0 Hz, 4H), 1.53 (d, J = 19.4 Hz, 9H). Example 5 - Synthesis of N-(2-(2-(Methylthio)-10H-phenothiazin-10-yl)ethyl) adamantan-1-amine (Compound EA03)
Synthesis of 2-Chloro-1-(2-(methylthio)-10H-phenothiazin-10-yl)ethan-1-one: 2-(Methylthio)-10H-phenothiazine (0.315 g, 1.28 mmol) and chlorobenzene (5 mL) were added to a microwave vial (20 mL) together with a magnetic stirrer bar. Chloroacetic chloride (0.25 mL, 3.14 mmol) was carefully added while stirring. After addition of chloroacetic chloride the mixture was capped and put in the microwave for 30 min at 120°C (in addition to 10 min of pre-stirring), whereupon the mixture was cooled and water added (5 mL). The mixture was extracted with ethyl acetate (10 mL x 3), the extracts were combined and washed with brine. The organic layer was dried over Na2SO4, filtered and the solvent removed under reduced pressure. The compound was recrystallized in methanol resulting in light yellow crystals in a yield of 72% (0.297 g, 0.92 mmol). 1H NMR (500 MHz, CDCl3) δ 7.48 (d, J = 7.8 Hz, 1H), 7.40 (s, 1H), 7.37 (dd, J = 7.8, 1.5 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.20 – 7.16 (m, 1H), 7.06 (dd, J = 8.3, 2.0 Hz, 1H), 4.10 (d, J = 6.3 Hz, 2H), 2.42 (s, 3H).13C NMR (126 MHz, CDCl3) δ 165.64, 138.68, 138.44, 137.69, 129.21, 128.21, 128.12, 127.55, 127.39, 126.53, 125.65, 124.18, 41.78, 15.97. Synthesis of 10-(2-Chloroethyl)-2-(methylthio)-10H-phenothiazine: 2-Chloro-1-(2-(methylthio)-10H-phenothiazin-10-yl)ethan-1-one (0.317 g, 0.98 mmol) and dry THF (5 ml) were added to a dry round bottle flask (25 mL) equipped with a magnetic stirring bar. The mixture was flushed with nitrogen and put in an ice water bath and BF3 • Et2O (0.20 mL, 1.62 mmol) carefully added by syringe while stirring. NaBH4 (0.045 g, 1.19 mmol) was added and the mixture was stirred for 1 h. The mixture was then placed in an ultrasonic bath for 2 h. After removing the mixture from the ultrasonic bath, it was quenched with NaHCO3 and then extracted with ethyl acetate (10 mL x 3). The organic phases were combined and dried over Na2SO4, filtered and solvent was removed under reduced pressure to obtain a thick oil in a yield of 90% (0.272 g, 0.88 mmol). 1H NMR (500 MHz, CDCl3) δ 7.18 – 7.12 (m, 2H), 7.04 (d, J = 8.0 Hz, 1H), 6.94 (td, J = 7.5, 1.2 Hz, 1H), 6.87 – 6.82 (m, 2H), 6.77 (d, J = 1.8 Hz, 1H), 4.22 – 4.18 (m, 2H), 3.79 – 3.75 (m, 2H), 2.46 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 144.86, 144.02, 138.00, 127.82, 127.75, 127.50, 125.54, 123.26, 122.29, 121.36, 115.43, 114.21, 49.32, 39.94, 16.43.
Synthesis of N-(2-(2-(Methylthio)-10H-phenothiazin-10-yl)ethyl)adamantan-1- amine EA03: 10-(2-Chloroethyl)-2-(methylthio)-10H-phenothiazine (0.202 g, 0.66 mmol), KI (0.138, g, 0.83 mmol), adamantylamine (0.493 g, 3.25 mmol), and DMF (5 mL) were added to a round bottle flask (50 mL) equipped with a magnetic stirrer bar. The mixture was heated at 100°C and stirred for 24 h. An NH4Cl solution (5 mL) was added and then extracted with (10 mL x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were then filtered, and solvent was removed under reduced pressure to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate : hexane = 9:1 and 1% Et3N) resulting in a pink waxy compound in a yield of 53% (0.148 g, 0.35 mmol). Rf = 0.21 (ethyl acetate: hexane = 9:1). 1H NMR (500 MHz, CDCl3) δ 7.17 – 7.12 (m, 2H), 7.05 (d, J = 7.9 Hz, 1H), 6.94 – 6.89 (m, 2H), 6.86 – 6.82 (m, 2H), 4.02 (t, J = 6.4 Hz, 2H), 2.97 (t, J = 6.4 Hz, 2H), 2.46 (s, 3H), 2.01 (s, 3H), 1.62 (d, J = 11.9 Hz, 3H), 1.53 (d, J = 2.9 Hz, 9H).13C NMR (126 MHz, CDCl3) δ 145.68, 144.73, 137.71, 127.57, 127.52, 127.31, 125.71, 122.86, 122.58, 121.19, 116.05, 114.93, 50.80, 48.04, 42.37, 37.31, 36.59, 29.49, 16.51. Example 6 – Synthesis of N-(2-(2-(Ethylthio)-10H-phenothiazin-10-yl)ethyl) adamantan-1-amine (Compound EA06)
Synthesis of 2-Chloro-1-(2-(ethylthio)-10H-phenothiazin-10-yl)ethan-1-one: 2-(Ethylthio)-10H-phenothiazine (0.305 g, 1.18 mmol) and 5 ml of chlorobenzene were added to a microwave vial (20 mL) together with a magnetic stirring bar. Chloroacetic chloride (0.25 mL, 3.14 mmol) was carefully added while stirring. After addition of chloroacetic chloride, the vial was sealed and placed in the microwave
oven cavity for 30 min at 120°C (in addition to 10 min of pre-stirring), whereupon water (5 mL) was added. The mixture was extracted with ethyl acetate (10 mL x 3), the extracts were combined and washed with brine. The organic layer was dried over Na2SO4, filtered and the solvent removed under reduced pressure. The compound was recrystallized in methanol resulting in light yellow crystals in a yield of 86% (0.339 g, 1.01 mmol). 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 8.7 Hz, 2H), 7.46 (d, J = 7.7 Hz, 1H), 7.38 – 7.32 (m, 2H), 7.28 (d, J = 7.6 Hz, 1H), 7.21 (dd, J = 8.2, 1.9 Hz, 1H), 4.18 (d, J = 9.7 Hz, 2H), 3.05 – 2.88 (m, 2H), 1.34 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 165.48, 138.35, 137.73, 136.79, 128.20, 128.09, 127.82, 127.53, 127.40, 126.51, 41.77, 27.81, 14.24. Synthesis of 10-(2-Chloroethyl)-2-(ethylthio)-10H-phenothiazine: 2-Chloro-1-(2-(ethylthio)-10H-phenothiazin-10-yl)ethan-1-one (0.244 g, 0.73 mmol) and dry THF (5 mL) were added to a dry round bottle flask (25 mL) equipped with a magnetic stirring bar. The mixture was flushed with nitrogen and put in an ice water bath and BF3 • Et2O (0.15 mL, 1.22 mmol) carefully added by syringe while stirring. NaBH4 (0.039 g, 1.03 mmol) was added and the mixture was stirred for 1 h. The mixture was then placed on an ultrasonic bath for 2 h. After removing the mixture from the ultrasonic bath, it was quenched with NaHCO3 and then extracted with ethyl acetate (20 mL x 3). The organic phases were combined and dried over Na2SO4, filtered and solvent was removed under reduced pressure resulting in a thick oil in a yield of 86% (0.202 g, 0.63 mmol). 1H NMR (500 MHz, CDCl3) δ 7.19 – 7.13 (m, 2H), 7.05 (d, J = 8.0 Hz, 1H), 6.97 – 6.91 (m, 2H), 6.88 – 6.83 (m, 2H), 4.24 – 4.18 (m, 2H), 3.80 – 3.75 (m, 2H), 2.92 (q, J = 7.4 Hz, 2H), 1.30 (t, J = 7.3 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 144.81, 144.04, 135.98, 127.77, 127.75, 127.52, 125.43, 123.89, 123.25, 116.54, 115.40, 49.29, 39.89, 28.26, 14.43. Synthesis of N-(2-(2-(Ethylthio)-10H-phenothiazin-10-yl)ethyl)adamantan-1-amine EA06: 10-(2-Chloroethyl)-2-(ethylthio)-10H-phenothiazine (0.194 g, 0.63 mmol) KI (0.140 g, 0.84), adamantylamine (0.456 g, 3.02 mmol) and DMF (5 mL) were added to a round bottle flask (50 mL) equipped with a magnetic stirrer bar. The mixture was heated to 100°C and stirred for 24 h. An NH4Cl solution (5 mL) was added, before
it was extracted with (10 mL x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were then filtered and dried under reduced pressure to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate: hexane = 9:1 and 1% Et3N) obtaining a waxy compound in a yield of 14% (0.039 g, 0.09 mmol). Rf = 0.35 (ethyl acetate: hexane = 9:1). 1H NMR (500 MHz, CDCl3) δ 7.07 (t, J = 7.5 Hz, 2H), 6.97 (d, J = 8.4 Hz, 1H), 6.87 – 6.81 (m, 4H), 3.91 (t, J = 6.4 Hz, 2H), 2.88 (t, J = 6.4 Hz, 2H), 2.82 (q, J = 7.3 Hz, 2H), 1.92 (s, 3H), 1.58 – 1.50 (m, 3H), 1.45 (dd, J = 22.8, 2.9 Hz, 9H), 1.21 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 145.58, 144.85, 135.52, 127.51, 127.31, 125.59, 123.78, 123.61, 122.81, 117.46, 116.03, 50.33, 48.29, 42.59, 37.28, 36.66, 29.53, 28.37, 14.52. Example 7 - Synthesis of 10-((1-methylpiperidin-2-yl)methyl)-2-(methylthio)-10H- phenothiazine (Compounds EA07, EA08)
Synthesis of 2-(chloromethyl)-1-methylpiperidine: To a solution of (1-methylpiperidin-2-yl)methanol (0.53 g, 4.08 mmol) in dichloromethane (5 mL) was added 0.59 mL (0.96 g, 8.07 mmol, 2.0 eq) thionyl chloride. After heating under reflux overnight the solution was neutralized with saturated aqueous NaHCO3 and extracted with dichloromethane. The organic phase was dried over NaSO4 and the solvent removed under reduced pressure. The product was obtained as a brown liquid in a yield of 90% (0.540 g, 3.66 mmol). 1H NMR (300 MHz, CDCl3) δ [ppm] - 3.67 (dd,2J = 11.6 Hz,3J = 5.1 Hz, 1H), 3.56 (dd,2J = 11.6 Hz, 3J = 2.5 Hz, 1H), 2.88 (tdd, 3J = 11.6 Hz, 3J = 2.5 Hz, 3J = 3.5 Hz, 1H), 2.31 (s, 3H), 2.14-2.09 (m, 2H), 1.80-1.58(m, 5H), 1.35-1.27(m, 1H).
Synthesis of 10-((1-methylpiperidin-2-yl)methyl)-2-(methylthio)-10H-phenothiazine (EA07, EA08): 2-(methylthio)-10H-phenothiazine (0.36 g, 1.50 mmol) was dissolved in DMSO (2 mL). The flask was flushed with argon before the addition of KOH (0.25 g, 4.50 mmol). The solution was stirred at 80°C for 4h. KI (spatula tip) and 2- (chloromethyl)-1-methylpiperidine (0.22 g, 1.55 mmol) were added and the solution was stirred overnight at 110°C. After extracting three times with ethyl acetate, washing with brine and drying over NaSO4, the crude product was purified by column chromatography with hexane : ethyl acetate = 1:20. Two fractions were identified to be products – fraction 1 was a red solid in a yield of 6% (0.030 g, 0.08 mmol) while fraction 2 was a red solid in a yield of 11% (0.260 g, 0.17 mmol). Fraction 1 (EA07, R): 1H NMR (300 MHz, CDCl3) δ [ppm] - 7.15-6.80 (m, 7H), 4.28 (sex, 1H), 3.14 (dd, 2J = 13.3 Hz, 3J = 6.2 Hz, 1H), 3.04 (dd,2J = 13.3 Hz,3J = 4.8 Hz, 1H), 2.72-2.68 (m, 1H), 2.60-2.56 (m,1H), 2.49 (s, 3H), 2.44 (s, 3H), 2.01-1.95 (m, 1H), 1.84-1.73 (m, 3H), 1.68-1.61 (m, 1H). Fraction 2 (EA08, S): 1H NMR (300 MHz, CDCl3) δ [ppm] - 7.16-7.13 (m, 2H), 7.05- 7.03(d, 1H), 6.94-6.90 (dt, 1H), 6.87-6.85 (d, 1H), 6.83-6.80 (d, 1H), 6.79-6.78 (d, 1H), 4.24 (dd, 2J = 13.9 Hz, 3J = 4.5 Hz, 1H), 3.72 (dd,2J = 13.8 Hz, 3J = 6.3 Hz, 1H), 2.82-2.78 (m, 1H), 2.45 (s, 3H), 2.43 (s, 3H) 2.38-2.33 (m, 1H), 2.12-2.09 (m, 1H), 1.70-1.67(m, 1H), 1.60-1.51 (m, 2H), 1.35-1.27 (m, 1H), 1.22-1.18 (m, 1H). Fraction 1 (EA07, R): 13C NMR (126 MHz, CDCl3) δ [ppm] - 127.4 (C-arom.), 127.4 (C-arom.), 127.2 (C-arom.), 122.5 (C-arom.), 120.9 (C-arom.), 117.0 (C-arom.), 116.0 (C-arom.), 62.7 (CH2), 61.7 (CH), 61.3 (CH2), 48.1 (CH3), 30.5 (CH2), 28.8 (CH2), 25.0 (CH2), 16.2 (CH3). Fraction 2 (EA08, S): 13C NMR (126 MHz, CDCl3) δ [ppm] - 127.7 (C-arom.), 127.7 (C-arom.), 127.3 (C-arom.), 122.8 (C-arom.), 121.0 (C-arom.), 116.0 (C-arom.), 114.5 (C-arom.), 60.6 (CH), 57.1 (CH2), 51.1 (CH2), 43.6 (CH3), 30.5 (CH2), 25.8 (CH2), 23.9 (CH2), 16.4 (CH3).
Example 8 - Synthesis of 2-Chloro-10-((1-methylpiperidin-2-yl)methyl)-10H- phenothiazine (Compounds EA09, EA10)
2-(Chloromethyl)-1-methylpiperidine (150 mg, 1.02 mmol) was dissolved in DMSO (4 mL), 2-chloro-10H-phenothiazine (240 mg, 1.02 mmol), KOH (170 mg, 3.05 mmol) and KI (a spatula tip) were added. The mixture was heated under reflux overnight. Water (10 mL) was added, extracted with ethyl acetate (3 × 5 mL), the aqueous phase was acidified with HCl (3 M) to pH 3 and extracted again with ethyl acetate (3 × 5 mL). The organic phase was washed with brine and dried over NaSO4. The purification was performed with column chromatography with hexane/ethyl acetate-gradient (40:1-10:1). Two fractions were identified to be products. Fraction 1 was a pink solid in a yield of 7% (0.026 g, 0.08 mmol). Fraction 2 was a green solid in a yield of 31% (0.110 g, 0.32 mmol). Fraction 1 (EA09, R): 1H NMR(300 MHz,, CDCl3) δ [ppm] - 7.17-7.06 (m, 4H), 7.00(d, 1H), 6.92 (dt, 1H), 6.87 (d, 1H), 4.25 (sex, 1H), 3.10 (dd,2J = 13.2 Hz, 3J = 6.3 Hz, 1H), 3.01 (dd, 2J = 13.2 Hz, 3J = 4.8 Hz, 1H), 2.72-2.68 (m, 1H),2.60-2.55 (m, 1H), 2.50-2.43 (m, 3H+1H), 2.00-1.93 (m, 1H), 1.84-1.73 (m, 3H), 1.67-1.61 (m, 1H). Fraction 2: (EA10, S): 1H NMR(300 MHz, CDCl3) δ [ppm] - 7.18-7.13 (m, 2H), 7.03 (d, 1H), 6.95 (t,1H), 6.90-6.84 (m, 3H), 4.19 (dd,2J = 13.9 Hz, 3J = 4.9 Hz, 1H), 3.69 (dd, 2J = 13.9 Hz, 3J = 6.3 Hz, 1H), 2.80 (m, 1H), 2.42 (s, 3H), 2.34 (m, 1H) 2.09 (td, 1H), 1.97 (m, 1H), 1.69 (m, 1H), 1.40-1.19 (m, 1H). Fraction 1: (EA09, R): 13C NMR (126 MHz, CDCl3) δ [ppm] - 127.8 (C-arom.), 127.5 (C-arom.), 127.4 (C-arom.), 122.8 (C-arom.), 122.2 (C-arom.), 117.6 (C-arom.), 117.3 (C-arom.), 62.3 (CH2), 61.9 (CH), 61.2 (CH2), 48.0 (CH3), 30.3 (CH2), 28.7 (CH2), 25.0 (CH2). Fraction 2: (EA10, S): 13C NMR (126 MHz, CDCl3) δ [ppm] - 128.1 (C-arom.), 127.8 (C-arom.), 127.5 (C-arom.), 123.1 (C-arom.), 122.5 (C-arom.), 116.2 (C-arom.),
116.0 (C-arom.), 60.4 (CH), 57.1 (CH2), 51.2 (CH2), 43.6 (CH3), 30.4 (CH2), 25.8 (CH2), 23.8 (CH2), 16.4 (CH3). Example 9 - Synthesis of N-benzyl-2-(10H-phenothiazin-10-yl)ethan-1- amine (Compound EA16)
10-(2-Chloroethyl)-10H-phenothiazine (0.219 g, 0.83 mmol) KI (0.159 g, 0.95 mmol), benzylamine (0.42 ml, 3.80 mmol) and DMF (5 mL) were added to a 50 mL round bottle flask equipped with a magnetic stirrer. The mixture was heated to 100°C and stirred overnight. An NH4Cl solution (5 mL) was added, before it was extracted with (10 mL x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were then filtered and dried under reduced pressure to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate: hexane = 3:7 and then increasing the amount of ethyl acetate) obtaining a waxy blue compound with a yield of 6% (0.016 g, 0.048 mmol). Rf = 0.11 (ethyl acetate: hexane = 3:7). 1H NMR (500 MHz, CDCl3) δ 7.17 – 7.11 (m, 5H), 7.10 – 7.01 (m, 4H), 6.89 – 6.78 (m, 4H), 4.01 (t, J = 6.1 Hz, 2H), 3.71 (s, 2H), 2.93 (t, J = 6.1 Hz, 2H).13C NMR (126 MHz, CDCl3) δ 145.09, 128.42, 128.09, 127.58, 127.33, 127.06, 125.75, 122.77, 115.80, 53.18, 46.85, 45.06.
Example 10 - Synthesis of 10-(2-(Piperidin-1-yl)ethyl)-10H-phenothiazine (Compound EA17)
10-(2-Chloroethyl)-10H-phenothiazine (0.165 g, 0.63 mmol) KI (0.222 g, 1.32 mmol), piperidine (0.28 ml, 2.85 mmol) and DMF (5 mL) were added to a 50 mL round bottle flask equipped with a magnetic stirrer. The mixture was heated to 100°C and stirred overnight. An NH4Cl solution (5 mL) was added and then extracted with ethyl acetate (10 mL x 3). The organic extracts were combined, washed with brine, and dried over NaSO4. The organic extracts were then filtered and dried under reduced pressure to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate:hexane = 9:1) initially. The compound was flushed out with MeOH obtaining a waxy compound in a yield of 75% (0.147 g, 0.47 mmol). 1H NMR (500 MHz, CDCl3) δ 7.14 – 7.04 (m, 4H), 6.91 – 6.83 (m, 4H), 4.14 (t, J = 6.7 Hz, 2H), 2.88 (t, J = 6.6 Hz, 2H), 2.65 (s, 4H), 1.65 (p, J = 5.7 Hz, 4H), 1.41 (s, 2H).13C NMR (126 MHz, CDCl3) δ 144.78, 127.65, 127.54, 125.33, 122.92, 115.59, 55.15, 54.26, 44.03, 24.59, 23.32. Example 11 - Synthesis of 10-(2-(Azepan-1-yl)ethyl)-10H-phenothiazine (Compound EA20)
10-(2-Chloroethyl)-10H-phenothiazine (0.206, 0.78 mmol), azepane (0.43 ml, 3.82 mmol), K2CO3 (0.600 g, 4.34 mmol), KI (0.128, 0.77 mmol) and THF (20 mL) were added to a round bottle flask (100 mL) equipped with a condenser and a magnetic
stirrer bar. The mixture was heated to reflux and stirred overnight. After stirring the mixture was cooled to room temperature and water added (20 mL), before it was extracted with ethyl acetate (3 × 20 mL). The organic extracts were dried over Na2SO4, filtered before the solvent was removed under reduced pressure to obtain a blue solid. The compound was purified using flash column chromatography (ethyl acetate: hexane = 9:1) obtaining a waxy compound in a yield of 13% (0.034 g, 0.10 mmol). Rf = 0.11 (ethyl acetate: hexane = 9:1). 1H NMR (500 MHz, CDCl3) δ 7.09 – 7.02 (m, 4H), 6.88 (dd, J = 8.2, 1.2 Hz, 2H), 6.82 (td, J = 7.5, 1.2 Hz, 2H), 3.96 – 3.88 (m, 2H), 2.87 – 2.80 (m, 2H), 2.69 – 2.62 (m, 4H), 1.63 – 1.49 (m, 8H).13C NMR (126 MHz, CDCl3) δ 127.41, 124.62, 122.48, 115.48, 56.71, 54.46, 46.69, 28.56, 27.03. Example 12 - Synthesis of N-(4-(10H-phenothiazin-10-yl)butyl)adamantan-1-amine (Compound EA22)
EA22 Synthesis of 10-(4-chlorobutyl)-10H-phenothiazine: Phenothiazine (1.436 g, 7.21 mmol), anhydrous DMF (10 mL) and NaH (0.260 g, 10.8 mmol) were added to a dry round bottle flask (50 mL) equipped with a magnetic stirring bar. The flask was placed in an ice-water bath and 1-bromo-4- chlorobutane (0.82 ml, 7.11 mmol) was added to the flask. The mixture was capped and stirred for 1 h in an ice water bath and stirred for 18 h at 20°C. Water (50 mL) was added to the flask and the organic phase was extracted using ethyl acetate (50 mL × 3). The organic phases were combined and dried over anhydrous Na2SO4, filtered and the solvent removed under reduced pressure using a rotary evaporator. The compound was then purified using flash chromatography (hexane : ethyl acetate = 85:15) resulting in a solid product in a yield of 26% (0.532 g, 1.84 mmol). 1H NMR (500 MHz, CDCl3) δ 7.19 – 7.11 (m, 4H), 6.96 (m, 1H), 6.91 (td, J = 7.5, 1.2 Hz, 2H), 6.85 (m, 1H), 3.88 (t, J = 6.6 Hz, 2H), 3.51 (t, J = 6.3 Hz, 2H), 2.00 –
1.83 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 145.19, 127.62, 127.30, 125.47, 122.63, 115.57, 46.32, 44.75, 29.76, 24.11. Synthesis of N-(4-(10H-phenothiazin-10-yl)butyl)adamantan-1-amine: 10-(4-chlorobutyl)-10H-phenothiazine (0.532 g, 1.84 mmol), KI (0.304 g, 1.84 mmol), adamantylamine (1.382 g, 9.14 mmol) and DMF (5 mL) were added to a round bottle flask (25 mL) equipped with a magnetic stirring bar. The mixture was heated at 100°C and stirred for another 18 h. The mixture was then lowered to 20°C whereupon saturated aqueous solution of NH4Cl (5 mL) was added. The organic phase was extracted with ethyl acetate (3 × 10 mL). The organic phases were combined, dried over anhydrous Na2SO4, filtered, and the solvent removed under reduced pressure using a rotary evaporator. The crude product was purified using flash chromatography (hexane : ethyl acetate = 30:70) Rf = 0.06. A solid blue crystal was isolated (0.562 g, 1.39 mmol) in a yield of 75%. 1H NMR (500 MHz, CDCl3) δ 7.20 – 7.09 (m, 4H), 6.94 – 6.83 (m, 4H), 3.87 (t, J = 7.1 Hz, 2H), 2.65 – 2.60 (t, J = 7.5 Hz, 2H), 1.85 (p, J = 7.6 Hz, 4H), 1.68 – 1.55 (m, 15H). 13C NMR (126 MHz, CDCl3) δ 145.21, 127.45, 127.24, 124.97, 122.41, 115.45, 51.19, 47.12, 42.38, 39.94, 36.64, 29.54, 28.22, 24.80. Example 13 - Synthesis of N-(3-(10H-phenothiazin-10-yl)propyl)adamantan-1- amine (Compound EA23)
EA23 Synthesis of 3-chloro-1-(10H-phenothiazin-10-yl)propan-1-one: 10H-phenothiazine (5.00 g, 25.09 mmol) and 80 ml toluene were added to a round bottle flask (500 mL) equipped with a magnetic stirring bar. The mixture was immersed into an ice-water bath and stirred before 3-chloropropanoyl chloride (3.60 mL, 37.64 mmol) was carefully added by syringe. The mixture was heated at 80°C and stirred for 20 h. The mixture was then cooled to 20°C and the solvent was removed under reduced pressure. The compound was then purified by
recrystallisation in methanol, resulting in white crystals in a yield of 87% (6.346 g, 21.90 mmol). 1H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 7.9 Hz, 2H), 7.39 (dd, J = 7.8, 1.5 Hz, 2H), 7.27 (td, J = 7.7, 1.5 Hz, 2H), 7.18 (td, J = 7.6, 1.4 Hz, 2H), 3.73 (t, J = 6.9 Hz, 2H), 3.00-2.75 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 168.84, 138.22, 128.14, 127.14, 39.63, 37.34. Synthesis of 10-(3-chloropropyl)-10H-phenothiazine: 3-chloro-1-(10H-phenothiazin-10-yl)propan-1-one (2.002 g, 6.90 mmol) and dry THF (45 mL) were transferred to a dry round bottle flask (250 mL) equipped with a magnetic stirring bar. The mixture was flushed with nitrogen and immersed into an ice-water bath. Then, under gentle stirring, BF3•Et2O (1.4 mL, 11.32 mmol) was carefully added by means of a syringe. NaBH4 (0.330 g, 8.70 mmol) was added to the mixture then heated at reflux and stirred for 24 h. The post-reaction mixture was cooled to 20°C and quenched with saturated aqueous solution of NaHCO3. Then the mixture was extracted with ethyl acetate (3 x 50 mL). The organic phases were combined and dried over Na2SO4, filtered, and the solvent was removed under reduced pressure. The compound was purified using flash column chromatography (ethyl acetate : hexane = 1:9) to obtain a brown waxy compound in a yield of 37% (0.697 g, 2.53 mmol). 1H NMR (600 MHz, CDCl3) δ 7.03 (td, J = 7.2, 1.5 Hz, 4H), 6.80 (td, J = 7.4, 1.2 Hz, 2H), 6.76 (dd, J = 8.6, 1.3 Hz, 2H), 3.92 (t, J = 6.6 Hz, 2H), 3.51 (t, J = 6.2 Hz, 2H), 2.08 (p, J = 6.4 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 145.11, 127.71, 127.42, 125.72, 122.83, 115.67, 44.01, 42.56. Synthesis of N-(3-(10H-phenothiazin-10-yl)propyl)adamantan-1-amine EA23: 10-(3-chloropropyl)-10H-phenothiazine (0.697 g, 2.53 mmol), KI (0.418 g, 2.53 mmol) adamantyl-amine (1.152 g, 7.58 mmol) and DMF (10 mL) were added to a round bottle flask (50 mL) equipped with a magnetic stirrer bar. The mixture was heated to 100°C and stirred for 24 h. 15 ml of a saturated aqueous solution of NH4Cl were added, in addition to 50 ml water before it was extracted with (50 ml x 3) ethyl acetate. The organic extracts were combined, washed with brine and dried over NaSO4. The organic extracts were filtered, and solvent removed in vacuo, to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate: hexane 9:1 and 1% Et3N), to obtain a brown
waxy compound in a yield of 41% (0.401 g, 1.03 mmol). Rf = 0.17 (ethyl acetate: hexane 9:1). 1H NMR (500 MHz, CDCl3) δ 7.15-7.10 (m, 4H), 6.91 – 6.86 (m, 4H), 3.93 (t, J = 6.7 Hz, 2H), 2.70 (t, J = 6.9 Hz, 2H), 2.02-1.98 (m, 3H), 1.90 (p, J = 6.8 Hz, 2H), 1.66 – 1.59 (m, 3H), 1.57-1.50 (m, 9H).13C NMR (126 MHz, CDCl3) δ 145.29, 127.40, 125.21, 122.40, 115.65, 50.37, 45.41, 44.21, 42.74, 41.84, 37.94, 36.77, 36.25, 35.87, 30.94, 29.59, 29.29, 28.52. Example 14 - Synthesis of N-(adamantan-1-yl)methyl)-2-(10H-phenothiazin-10- yl)ethan-1-amine (Compound EA24)
10-(2-Chloroethyl)-10H-phenothiazine (0.507 g, 1.94 mmol), KI (0.324 g, 1.95 mmol) 1-adamantanemethylamine (0.5 mL, 2.82 mmol) and DMF (10 ml) were added to a round bottle flask (50 mL) equipped with a magnetic stirrer bar. The mixture was then heated at 100°C and stirred for 24 h. A saturated aqueous solution of NH4Cl (15 mL) and water (50 mL) was added before the mixture was extracted with (3 × 50 mL) ethyl acetate. The organic extracts were combined, washed with brine, dried over anhydrous NaSO4, filtered, and finally the organic solvent was removed under reduced pressure to obtain a dark coloured sticky compound. The compound was purified using flash column chromatography (ethyl acetate : hexane = 9:1 and 1% Et3N) that delivered a brown waxy compound in a yield of 52% (0.397 g, 1.02 mmol). Rf = 0.25 (ethyl acetate : hexane = 9:1). 1H NMR (500 MHz, CDCl3) δ 7.10 – 7.04 (m, 4H), 6.88 – 6.82 (m, 4H), 3.96 (t, J = 6.1 Hz, 2H), 2.90 (t, J = 6.0 Hz, 2H), 2.09 (s, 2H), 1.86-1.80 (m, 3H), 1.63-1.56 (m, 3H), 1.55-1.48 (m, 3H), 1.37-1.32 (m, 6H).13C NMR (126 MHz, CDCl3) δ 145.19, 127.51, 127.26, 125.77, 122.68, 115.89, 62.48, 47.39, 46.92, 40.69, 37.17, 33.43, 30.94, 28.43.
Example 15 - In vitro activity in cell lines Method: Cells from various cell lines (LN18, T98G, U87-MG, U251, NHA, SV80, P3XX) were seeded 20-24 h before the treatment in a 96-well plate to approximately 30% confluency and kept at 37°C in a humidified 5% CO2 atmosphere. The live cell IncuCyte Zoom imaging system (Essen BioScience) was used to assess the proliferation of the different cell lines in response to the compounds EA01 and EA02 in different concentrations. Brightfield microscopy images were captured at 2 h intervals over the whole treatment period of 72 h and the percentage of confluency was analyzed with the IncuCyte Zoom Software. Results: Figure 1 shows the monitored confluency in 96 wells after a treatment for 72 h with 4 µM EA01 in three different cell lines using the IncuCyte Zoom. The glioblastoma cell lines U87-MG and U251 (see B and C) show reduced cell viability and proliferation assessed via percentage of confluency when treated with 4 µM EA01 compared to cells grown in media only (DMEM alt). The control cell line NHA (see Figure 1A) is not affected by treatment with 4 µM EA01. Figure 2 shows the measured confluency percentage means normalised to the confluency percentage of time point 0 h (= change fold of confluency) for various treatment conditions of U87-MG, p44-46 (n=3) over 72 h (Figure 2A) and to the endpoint 72 h (B) with and without Temozolomide in combination with EA01 and EA02. Temozolomide is not adding to the treatment effect of EA01 and EA02. Both compounds lead to reduced proliferation and cell death for the tested glioblastoma cell lines U87-MG and U251 in lower concentrations compared to normal human astrocytes (NHA) as control cell line. Example 16 - Cell Viability Assay Method: The effect of the compounds EA01-EA10, EA16, EA17, EA20 and EA22 on the viability of various cell lines (LN18, T98G, U87-MG, U251, NHA, SV80, P3XX) was assessed using the WST-1 Assay (Roche, 11644807001). Cells were seeded at a
concentration of 5000 cells × well-1 (or 10000 cells × well-1 for P3XX) in 96-well plates 20-24 h prior to treatment and kept at 37°C in a humidified 5% CO2 atmosphere. The cells were treated with various concentrations of the compounds for 72 h before the WST-1 reagent was added in a 1:10 ratio dependent on the well media volume. A 30 second-shaking period on a linear shaker was followed by an incubation for 3 hours at 37°C. The proliferation rate was determined by measuring the absorbance at 450 nm with a microplate photometer (Multiskan FC, ThermoFisher Scientific). LC50 values were determined for the different cell lines using the WST1 assay. Log P data was also calculated. Results: LC50 values in µM for EA01 and EA02 are shown in Table 1 for different glioblastoma and control cell lines. Table 1
EA00=Thioridazine. NHA (normal human astrocytes) used as reference. Log P estimated by means of “Chemical properties” of ChemDraw Professional Example 17 - Effect of compounds on tumor spheroids Method: The effect of the compounds EA01 and EA02 was tested on the viability of 21-day old fetal rat brain organoids (FRBO) and on 5-day old tumor spheroids. FRBO were prepared according to a modified protocol as described in Bjerkvig et al., Cancer
Res.1986, 46(8), 4071-4079. Tumor spheroids of the stem-cell like cell lines P3, P3-GFP, BG5, BG5-GFP, BG7 and BG7-GFP were obtained by seeding 5000 cells per well in U-bottom 96-well plates. After centrifugation at 2000 rpm and 37°C for 90 min, cells were incubated at standard conditions. FRBO and tumor spheroids were treated with various concentrations of the compounds for 72 h before the WST-1 protocol was performed. Results: LC50 values for treatment of the different primary glioblastoma cell lines derived from patient material are displayed in Table 2, with and without GFP-labelling. EA01 has a higher toxicity than EA02 in all studied stem-cell like cell lines. The FRBO as a model for the adult human brain is not affected at these LC50 concentrations and tolerates a higher concentration of both EA01 and EA02 with an LC50 of approximately 18 µM for both compounds (see Figures 3A and 3B). Table 2
Example 18 - Co-culture Model Method: Old FRBO (21 day) and old tumor spheroids (5-day) of the sorted stem-cell like cell lines P3-GFP, BG5-GFP and BG7-GFP were confronted in U-bottom 96-well plates and treated with different concentrations of compound EA01 and EA02. After 24 h these co-cultures were then transferred to a µ-Slide 8 well glass chamber under continued treatment. Invasion of the tumor cells into the FRBO was observed using confocal microscopy (Andor Dragonfly 505) in time intervals of 24, 48 and 72 h. The co-cultures were quantified using Photoshop.
Results: Figure 4 shows brightfield and fluorescence confocal microscopy images of P3- GFP (Figure 4A) and BG5-GFP (Figure 4B) confronted with FRBO generation 33 after 72 h of treatment with EA01 and EA02. Consistent with the LC50 determination for both tumor spheroids and FRBO, advanced toxicity of both compounds for the tumor spheroids but not the FRBO was detected for the indicated concentrations of EA01 and EA02. Example 19 - Colony formation assay Method: LN18, U251 and NHA cells (125 cells per well) were seeded in 6-well culture plates in triplicate and incubated at 37°C in a humidified chamber of 5% CO2 for up 14 days. Colonies were washed with PBS, fixed in methanol for 10 min and stained with crystal violet for 10 min at room temperature. Colonies were counted when they were formed by more than 50 cells. Results: As shown in Figure 5, the control cell line NHA tolerated higher concentrations of EA01 compared to the glioblastoma cell lines (LN18, LN229, U251). Example 20 - In vivo toxicity screen in mice A first in vivo toxicity screen was performed in C57BL/6 male mice. EA01 and EA02 were dissolved in DMSO and diluted to the final concentrations. After randomization, the animals were stratified into a control group (DMSO, n=5) and the following treatment groups: EA017 mg × kg-1 (n=5), EA0114 mg × kg-1 (n=5), EA0121 mg × kg-1 (n=5), EA027 mg × kg-1 (n=5), EA0214 mg × kg-1 (n=5), and EA0221 mg × kg-1 (n=5). Treatment was administered once via intraperitoneal injection and the animals were observed closely. Euthanization and explantation of the organs (brain, heart, liver and kidney) was performed after 24, 48, 72 h (n=1 per group respectively) and 120 h (n=2 per group). Organs were formalin fixed and hematoxylin and eosin (H&E) stains were performed on the sections. All mice treated with EA01 and EA02 developed transient symptoms of drowsiness and recovered fully 15 min. after injection.
Example 21 - Cell viability assay in melanoma cell lines Method: The effect of the compounds EA01, EA02 and EA10 on various melanoma cell lines (H1, H3 and H10) was tested using the same protocol as in Example 14. Results: IC50 values are provided in Table 3: Table 3
* mean value of three replicates
Claims
Claims: 1. A compound of formula (Ib), a stereoisomer, or a pharmaceutically acceptable salt thereof, for use in the treatment of glioblastoma:
(Ib) wherein: A is an optionally substituted amine or an optionally substituted carbocyclic or heterocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2- groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl); each R1 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl); each R2 is independently selected from: C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3),
-S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl); n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2.
2. A compound for use as claimed in claim 1, wherein A is an optionally substituted carbocyclic or heterocyclic ring system.
3. A compound for use as claimed in claim 2, wherein A is an optionally substituted carbocyclic ring system.
4. A compound for use as claimed in claim 3, wherein A is an optionally substituted cycloalkyl or cycloalkenyl group, preferably an optionally substituted cycloalkyl group containing two or three rings which are fused or bridged.
5. A compound for use as claimed in claim 2, wherein A is an optionally substituted heterocyclic group.
6. A compound for use as claimed in claim 2, wherein A is selected from substituted or unsubstituted adamantyl, phenyl, quinuclidinyl, piperidinyl and azepanyl.
7. A compound for use as claimed in claim 6, wherein A is substituted or unsubstituted adamantyl, preferably unsubstituted adamantyl.
8. A compound for use as claimed in any one of the preceding claims, wherein A is substituted by one or more groups independently selected from -OH, C1-6 alkyl, -O-C1-6 alkyl, C1-6 haloalkyl, and halogen atoms (e.g. F, Cl or Br).
9. A compound for use as claimed in any one of the preceding claims, wherein A is selected from the following:
10. A compound for use as claimed in any one of the preceding claims, wherein L is an optionally substituted, straight-chained or branched C1-6 alkylene group.
11. A compound for use as claimed in any one of claims 1 to 9, wherein L is an optionally substituted C1-6 alkylene group, preferably C2-6 alkylene group, in which one or more -CH2- groups of the alkylene chain are replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl).
13. A compound for use as claimed in any one of the preceding claims, wherein each R1 is independently selected from C1-3 alkyl (e.g. -CH3), -CF3, -O-C1-3 alkyl (e.g. -OCH3 or -OCH2CH3), -S-C1-3 alkyl (e.g. -SCH3 or -SCH2CH3), F, Cl, Br and phenyl.
14. A compound for use as claimed in any one of the preceding claims, wherein n is 0, 1 or 2, preferably 0 or 1.
15. A compound for use as claimed in any one of the preceding claims, wherein each R2 is independently selected from C1-3 alkyl (e.g. -CH3), -CF3, -O-C1-3 alkyl (e.g. -OCH3 or -OCH2CH3), -S-C1-3 alkyl (e.g. -SCH3 or -SCH2CH3), F, Cl, Br and phenyl.
16. A compound for use as claimed in any one of the preceding claims, wherein m is 0, 1 or 2, preferably 0 or 1.
17. A compound for use as claimed in claim 1 which is selected from the following compounds, their stereoisomers, and their pharmaceutically acceptable salts:
18. A compound for use as claimed in any one of the preceding claims in the treatment of an astrocytoma, oligodendroglioma or ependymoma. 19. A compound of formula II, a stereoisomer or a pharmaceutically acceptable salt thereof:
wherein: A is an optionally substituted carbocyclic ring system; L is a linking group which is an optionally substituted C1-6 alkylene group in which one or more -CH2- groups of the alkylene chain may be replaced by a group independently selected from -O-, -S- and -NR’- (where R’ is H or C1-3 alkyl, e.g. methyl); each R1 and R2 is independently selected from:
C1-6 alkyl (preferably C1-3 alkyl, e.g. -CH3), C2-6 alkenyl (preferably C2-4 alkenyl), C2-6 alkynyl (preferably C2-4 alkynyl), C1-6 haloalkyl (e.g. -CF3), -O-C1-6 alkyl (preferably -O-C1-3 alkyl, e.g. -OCH3), -S-C1-6 alkyl (preferably -S-C1-3 alkyl, e.g. -SCH3), -OH, -SH, halogen (e.g. F, Cl or Br), and an optionally substituted aryl group (e.g. optionally substituted phenyl); n is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2; and m is an integer from 0 to 4, preferably 0 to 2, e.g.0, 1, or 2. 20. A compound as claimed in claim 19, wherein A is an optionally substituted cycloalkyl group, preferably an optionally substituted cycloalkyl group containing two or three rings which are fused or bridged. 21. A compound as claimed in claim 19, wherein A is substituted or unsubstituted adamantyl. 22. A compound as claimed in claim 19 having the formula EA01, EA02, EA03, EA04, EA05, EA06, EA13, EA14, EA22, EA23 or EA24 as defined in claim 17, or a stereoisomer or pharmaceutically acceptable salt thereof. 23. A pharmaceutical composition comprising a compound of formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof as claimed in any one of claims 19 to 22, together with one or more pharmaceutically acceptable carriers, excipients or diluents.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2111035.8A GB202111035D0 (en) | 2021-07-30 | 2021-07-30 | Therapy |
GB2111035.8 | 2021-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023007181A1 true WO2023007181A1 (en) | 2023-02-02 |
Family
ID=77651224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2022/052006 WO2023007181A1 (en) | 2021-07-30 | 2022-07-29 | Phenothiazine antipsychotics for use in the treatment of glioblastoma |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202111035D0 (en) |
WO (1) | WO2023007181A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048271A1 (en) * | 1998-12-02 | 2002-04-25 | Farzan Rastinejad | Methods and composition for restoring conformational stability of a protein of the p53 family |
WO2006017185A1 (en) * | 2004-07-09 | 2006-02-16 | Odyssey Thera, Inc. | Drugs for the treatment of neoplastic disorders |
US20130289023A1 (en) * | 2012-04-30 | 2013-10-31 | Chi-Ying Huang | Method for treating brain tumor |
WO2019229236A1 (en) * | 2018-05-31 | 2019-12-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nupr1 inhibition for treating cancer |
-
2021
- 2021-07-30 GB GBGB2111035.8A patent/GB202111035D0/en not_active Ceased
-
2022
- 2022-07-29 WO PCT/GB2022/052006 patent/WO2023007181A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048271A1 (en) * | 1998-12-02 | 2002-04-25 | Farzan Rastinejad | Methods and composition for restoring conformational stability of a protein of the p53 family |
WO2006017185A1 (en) * | 2004-07-09 | 2006-02-16 | Odyssey Thera, Inc. | Drugs for the treatment of neoplastic disorders |
US20130289023A1 (en) * | 2012-04-30 | 2013-10-31 | Chi-Ying Huang | Method for treating brain tumor |
WO2019229236A1 (en) * | 2018-05-31 | 2019-12-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nupr1 inhibition for treating cancer |
Non-Patent Citations (6)
Title |
---|
BJERKVIG ET AL., CANCER RES, vol. 46, no. 8, 1986, pages 4071 - 4079 |
CHENG H-W ET AL: "Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data", CELL DEATH & DISEASE, vol. 6, no. 5, 1 May 2015 (2015-05-01), pages e1753 - e1753, XP055969769, Retrieved from the Internet <URL:http://www.nature.com/articles/cddis201577> DOI: 10.1038/cddis.2015.77 * |
DONNIER-MARÉCHAL MARION ET AL: "Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 89, 18 October 2014 (2014-10-18), pages 198 - 206, XP029110639, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2014.10.053 * |
JOHANNESSEN ET AL., I NT J. CANCER, vol. 144, 2019, pages 1735 - 1745 |
KANG SEOKMIN ET AL: "Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R", MOLECULAR CANCER THERAPEUTICS, vol. 16, no. 1, 1 January 2017 (2017-01-01), US, pages 217 - 227, XP055956918, ISSN: 1535-7163, Retrieved from the Internet <URL:https://watermark.silverchair.com/217.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtEwggLNBgkqhkiG9w0BBwagggK-MIICugIBADCCArMGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMuJ1giUaJujsUcbY4AgEQgIIChI4Pr45eI6cBcecwLjKfpKiYCzM6GUqALCxmex-9IvhawUk14Wg1QdbuGqVd3UyXxvYv2VuKFLN27MLq4-0PrHBkdMTyFDiR> DOI: 10.1158/1535-7163.MCT-16-0169-T * |
SHIN SOON YOUNG ET AL: "The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells", CARCINOGENESIS, vol. 34, no. 9, 1 September 2013 (2013-09-01), GB, pages 2080 - 2089, XP055956920, ISSN: 0143-3334, Retrieved from the Internet <URL:https://watermark.silverchair.com/bgt169.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAuAwggLcBgkqhkiG9w0BBwagggLNMIICyQIBADCCAsIGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMdqYIe38hwVgVPnmoAgEQgIICk86k_V6wLV1XHQkmRPWsDDi0fKNt7y-MmvcvQMDk2WPHw4kvySTBNzUFrVW1zFiQBA7G9Q61_7PTAHhaYTS6XEMkn2rQG> DOI: 10.1093/carcin/bgt169 * |
Also Published As
Publication number | Publication date |
---|---|
GB202111035D0 (en) | 2021-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2717577C2 (en) | Imidazoisoindole derivative, method for production thereof and medical use | |
CN105481789B (en) | Indoleamine-2,3-dioxygenase inhibitor and preparation method thereof | |
EP2643300A1 (en) | Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases | |
JP2021176911A (en) | Estrogen receptor controlling medicine | |
CN113853379B (en) | Fluorine-containing compound and anticancer medical application | |
KR101800595B1 (en) | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | |
JP4932994B2 (en) | Anticancer calcium channel blocker | |
AU2022203554A1 (en) | Combination therapy for the treatment of cancer | |
BR122020007729B1 (en) | PIRIDONE AMIDE PRODRUGS, THEIR CRYSTALLINE FORMS AND PREPARATION PROCESS THEREOF | |
KR102157912B1 (en) | Enzyme-activating compounds and compositions | |
JP7475062B2 (en) | Multifunctional inhibitors of the MEK/PI3K and mTOR/MEK/PI3K biological pathways and methods of treatment using same | |
US11634407B2 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
JP6637890B2 (en) | Benzamide and nicotinamide compounds and methods of using the same | |
SI9300591A (en) | Water soluble camptothecin derivatives | |
EA035989B1 (en) | Crystalline forms and processes for the preparation of cannabinoid receptor modulators | |
WO2021055936A1 (en) | Small-molecule inhibitors for the β-catenin/b-cell lymphoma 9 protein−protein interaction | |
UA79286C2 (en) | Arylcarbonylpipererazines and heteroarylcarbonylpiperazines and their use in the treatment of benign and malignant tumors | |
PT754682E (en) | AMINOSTILBAZOL DERIVATIVES AND MEDICINAL PRODUCTS | |
JP2019510744A (en) | Substituted oxadiazole compounds, compositions containing the compounds and applications thereof | |
JPWO2005079845A1 (en) | Migraine prophylaxis | |
JP2019510755A (en) | 2,3-Epoxy succinyl derivatives, process for their preparation and use | |
WO2023007181A1 (en) | Phenothiazine antipsychotics for use in the treatment of glioblastoma | |
AU2017380492A1 (en) | Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof | |
JPS63264580A (en) | 3-(2-haloalkyl)-1,4-oxathiin and 2-(2- haloalkyl)-1,4-dithiin | |
NO328854B1 (en) | Bis- (N ', N'-bis- (2-haloethyl) amino) phosphoramidate, pharmaceutical composition comprising the compound, method of preparation and use of the compound. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22754147 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |